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ABSTRACT
Strict anti-pollution laws have drastically changed how pharmaceutical
manufacturers operate. Increased environmental awareness has forced
changes in the way that sustained release pharmaceuticals are manufactured .
Coatings which were once applied from organic solutions have been
reformulated into water based polymeric dispersions that, although effective,
cannot equal the performance of their predecessors. Research has led to
updated coatings composed of three time tested polymers; cellulose acetate,
ethylcellulose and methacrylic acid copolymer. Additionally, new coatings
have been manufactured from custom polymers which provide excellent
sustained release. Unfortunately, their development has not progressed
beyond the laboratory since regulatory bodies worldwide are reluctant to
approve new polymers for use in vivo. Clearly there exists a need for new
coating materials that are "environmentally friendly, " approvable for in vivo use,
and effective. An attempt was made to identify materials which, in addition to
imparting sustained release, could be used safely, without organic solvents.
The crosslinking of a water soluble polymer was decided to be the most feasible
means of achieving that goal. Hence hydroxyethylcellulose (HEC), a water
soluble, GRAS (generally recognized as safe) polymer was identified and
evaluated under various conditions. The ability to insolubilize films of HEC was
demonstrated when films containing riboflavin-5'-phosphate were exposed to
visible or ultraviolet light. The drug release controlling potential of those films
was demonstrated by their application to tablets containing model drugs, and
their subsequent insolubilization via visible light exposure. Release rates of
tablets with crosslinked coatings were determined in vitro and found to be
nearly zero order and well controlled, in both water and 0.1 N HCI. The

(

shortcomings of this technique lie in the difficulties in quantitatively assaying
the crossl inked polymer. Since the crosslinked polymer is largely water and
organo-insoluble, attempts were made to differentiate between crosslinked and
uncrosslinked polymer. To date none of the techniques evaluated provides a
means to differentiate between the HEC's. While analysis of the crosslinked
polymer has proven difficult, a system capable of providing for the sustained
release , composed entirely of GRAS materials and not requiring organic
solvents, has been realized.

(
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(
This work has been prepared in accordance with the manuscript format
option for dissertation preparation, as outlined in section 11-3 of The Graduate
Manual of the University of Rhode Island. Contained within is a body of work
divided in to three sections.
Included within Section I is Manuscript 1, a historical review, which
provides the reader with an introduction to the subject of this dissertation, a
statement of the hypothesis tested herein, and the specific objectives of my
research .
Section II is comprised of three manuscripts, contain the findings of the
research which comprises this dissertation. These three manuscripts, as well
as the one found in Section I are presented in the format required by the journal
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to which they will , or have been, submitted. Also included in Section II is a
compilation of the primary conclusions drawn from this research.
Section Ill contains three appendices containing, ancillary data
(information essential to, but not usually included in published manuscripts) and
other details pertinent to the understanding of the concepts presented in
Section II. Note that within the graphical representations of data presented in
this dissertation there may be "f' shaped error bars which depict the standard
deviation of that data from it's respective mean. This dissertation closes with a
complete listing of all the works cited in this dissertation, arranged in
alphabetically by the author's last name.
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SECTION I

Manuscript I ''The Sustained Release Coating of Solid Dosage
Forms: A Historical Review." A general introduction to this research .

A statement of the hypothesis tested in this dissertation.

A compilation of the specific objectives of this research .

Manuscript I

THE SUSTAINED RELEASE COATING OF SOLID DOSAGE FORMS:
A HISTORICAL REVIEW
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THE SUSTAINED RELEASE COATING OF SOLID DOSAGE FORMS:
A HISTORICAL REVIEW

ABSTRACT

The continued development of sustained release technology over the past
forty years has provided countless ways of producing long acting dosage forms.

Of all the methods proposed, coating has proven to be one of the most enduring.
Although many have attempted to introduce new sustained release coatings to
the marketplace, only three have been widely accepted. This paper seeks to
provide the reader with a historical review of sustained release coating and
examine the reasons why three materials, cellulose acetate, ethylcellulose and
methacrylic acid copolymer have dominated this technology.
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INTRODUCTION

The coating of tablets, granules, and other dosage forms has provided
manufacturers with a means to extend the utility of an active ingredient which
may have physical or biopharmaceutical shortcomings. Usually, great changes
in the in vivo performance of a problematic, yet effective drug can be imparted
by applying the proper coating to it.

Some of these changes , hiding an

unpleasant odor for example, may seem insignificant when looked at from a
biopharmaceutical standpoint.

However, it is rather easy to comprehend the

benefits of applying a thin, acid resistant coating to protect an acid labile drug
from the low pH of the stomach.

Several authors (1 ,2,3) have published reviews of pharmaceutical
coating which pay close attention to the techniques and equipment employed
for solid dosage forms . These reviews are an invaluable tool to the formulator
as they contain in depth descriptions of the most common coating processes,
including individual advantages and disadvantages. An added benefit to these
reviews is their near timelessness. While it is true that the science of coating
has evolved over the years , it is also true that the coating equipment which we
employ today is not much different than that which was used twenty or even
forty years ago.

The evolution of coating equipment has not proceeded rapidly, largely
due to the limited ways in which large amounts of material can be handled
efficiently.

A sim ilar evolutionary trend is evident for coating materials.
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Although progresses in polymer chemistry have allowed the development of
specialized polymer systems which provide any number of desired properties,
the conservative nature of the pharmaceutical industry has, until recently ,
allowed for the widespread usage of only a few.

Yet the introduction and

popularity of these engineered materials is largely responsible for transforming
pharmaceutical coating from an artform , guarded by a few skilled individuals, to
a science which can be readily duplicated, tailored to specific needs and
transferred between manufacturing sites.

Many contemporary sustained release coatings are really the direct
descendants of those that were first introduced in the 1950's.

While many

attempts have been made to introduce new coatings to the industry, those
systems which applied new technologies to extant polymers have proven most
successful. This paper seeks to provide the reader with a concise overview of
the coatings employed for sustained release, providing a brief history of the
most popular coating techniques, an examination of the reasons why products
are coated, and provide a historical review of sustained release coatings in the
pharmaceutical industry.

REASONS FOR COATING SOLID DOSAGE FORMS

To the layman, tablet coatings may appear as mere decoration added to
make tablets more attractive to the eye and pleasing to the palate. However,
just as the sugar coating on some chocolate candies keeps the chocolate from
melting in your hand, coatings on tablets provide a means to improve the
stability and performance of the drugs held within them . Of course coatings are

5
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not just a cosmetic placed on tablets to make them more inviting, although they
may be used as such. Sometimes an opaque coating is used to mask a mottled
or discolored tablet but, more frequently , coatings are used to modify the
biopharmaceutical properties of a drug or to compensate for physico-chemical
shortcomings which it may possess.

It is possible to remedy certain problems encountered in tabletting by
applying some type of coating. The nature of the problem is what ultimately
determines which type of coating is applied. Therefore, coatings can be loosely
placed into one of three categories, grouped by the shortcomings which they
are intended to overcome.

There are coatings which can alter the

biopharmaceutical profile of a drug and others which help counteract the
physical incompatibilities of some drugs. Lastly, there are coatings which are

(

used for purely cosmetic purposes.

Many authors have posed many reasons for coating tablets.

The

remainder of this section shall present those reasons which are still relevant
today and some others which are of historical interest.

Tablets and other solid dosage forms may be coated to:

Mask unpleasant tastes and odors
Hide mottled or discolored tablet surfaces
Prevent freshly prepared pills and troches from adhering to one another (4)
Protect from gastric fluids those drugs which are destroyed by acid
i.e. erythromycin (5)
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Prevent nausea , vomiting, or ulceration due to irritation (6)
Impart a delayed action component for repeat action tablets (4)
Protect a drug from oxygen, carbon dioxide, water, and light (5)
Prevent incompatibilities between medicaments in a combination tablet (6)
Provide a semipermeable membrane which limits the release of a drug from
it's respective dosage form

TABLET COATING: A HISTORICAL PERSPECTIVE

Modern coating can be traced to rather humble origins in the kitchens of
19th century confectioners who had perfected the "art" of pan coating (4 ). In
the confectioner's kitchen , methods were developed to cover sticky, sweet
candies with a bright layer of colored, sometimes flavored sugar, thus rendering

(

them non-sticking, easily transportable, and as pleasing to the eye as they are
to the palate.

One might speculate that pharmacists, often faced with

preparations that were difficult to handle, would welcome such a novel and
useful tool to their trade. Unfortunately, during most of the 19th century, nearly
all prescriptions were

prepared by extemporaneous compounding.

A

considerable amount of the pharmacist's time was spent preparing the
individual prescription so little could be devoted to a process as time consuming
as sugar coating. In fact, when necessary, most pill coating was performed by
simple techniques which provided a suitable means of keeping the pills from
sticking together or hiding their bad taste. Large batches of pills (and later,
tablets) were uncommon.

7
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However, the 19th century pharmacist did find it necessary to apply
some sort of coating to many of his products especially massed pills, troches,
lozenges, and tablets. The methods employed may seem quite primitive today,
but were an effective means of resolving some problems and had the
advantage of being easy and efficient to use with small amounts of material.

Perhaps the simplest of these coating methods was the application of a
small amount of finely divided chalk or confectioner's sugar to the moistened
surface of pills (4). This was accomplished with two pilling tiles, one sprinkled
with finely divided dusting powder, the other with a thin layer of gum arabic or
tragacanth mucilage through which the pills could be continually rolled until a
thin white coating was obtained. Color could be added by incorporating a small
amount of dye into the dusting powder. A variation of this method suggests that

(

the pills be moistened with an etherial solution of tolu balsam . The principle
advantage to this variation is that the pills would dry much more quickly due to
the rapid evaporation of the ether (4). Yet another adaptation of "dusting" was
Furley's process, which was quite popular in 19th century England.

The

principal difference between the two was the ingredients of the coating.
Tragacanth and sugar were used in place of dusting powder as the solid portion
while albumen, obtained from a fresh egg replaced gum arabic as the binder.
Other coating methods employed at the time varied in complexity ranging from
the simple (i.e. "gilding") to more complex methods including gelatin and sugar
coating . In most cases "complexity" meant the need for specialized equipment.

Of all the early coating methods "gilding" has been subject to the most
scrutiny. Today it seems somewhat absurd to cover a medicament with a metal
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which could severely retard or completely prevent it's release in invivo.
However, at the time it was one of the most elegant and readily available
methods to coat small quantities of pills. Another advantage to this method is
the excellent compatibility of gold with other chemicals. Detailed instructions for
gilding pills are published in many of the earlier all inclusive pharmaceutical
texts.

Parrishes, 4th ed. 187 4, describes several methods for gilding and

cautions the pharmacist to use only pure gold and limit the amount applied. A
point of interest in this nearly 120 year old work is the concern about dosage
form 's "solubility" (a reference to bioavailability). It states 'The former belief that
a coating with metallic leaf, if sufficient to hide the taste and smell of the pills,
would interfere with their solubility, has been very much modified by recent
experience" (4).

Indicating, if only on the most rudimentary level, that pills

coated with gold leaf could effectively release their medication in the

(

gastrointestinal tract.

While successful in their own right, "dusting" and "gilding" were gradually
replaced by "dipping" and pan coating.

Dipping, a process once nearly

forgotten , but recently resurrected in a refined form for several OTC
preparations (Tylenol Gelcaps) , is mentioned briefly in Parrishes and is
discussed at great length in Remington's 3rd ed. 1894 (7). Similar coverage of
sugar coating a technique whose popularity was ever growing at the turn of the
century, can also be found in these works.

Generally, pills were dip coated in one of three materials gelatin, keratin
and salol.

Of these three, gelatin was the most popular and versatile, while

keratin and salol were reserved for enteric coatings (8). This fairly simple and
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effective process for coating involved the placement of freshly prepared pills
onto Jong pins which were then dipped, several times, into a hot solution of
gelatin. After hardening, the pins were removed and the hole which they left
behind was filled with additional gelatin. This efficient process was well suited
for the extemporaneous compounding of pills and many machines which
improved the process were patented.

"Dip Coating" of pills was quite effective, regardless of the few
shortcomings of the method, however it was impossible to coat compressed
tablets in this manner because they could not be easily pierced with a needle.
A remedy to this problem and a better way to coat pills was invented by J.B.
Russell and later adopted by Parke, Davis & Co (7). This apparatus replaced
the pins, previously used to hold pills, with a suction device which covered one

(

half of the tablet. Tablets were still dipped in the gelatin solution and allowed to
cool. Once cool , another set of tubes with vacuum was applied to the opposite
side of the tablet while the first set was removed . Again the tablets were dipped
and allowed to cool. The result was a gelatin coated tablet or pill that did not
require further processing.

As the turn of the century approached, sugar coating in rotating pans
was becoming the coating standard in large pharmaceutical houses. Jn a large
company, product batches were of sufficient size to warrant the use of pan
coating.

Many thousand pills or tablets could be economically coated by

relatively few employees.

The era of modern pharmaceutical coating had

begun.
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During the first half of this century, tablet coating evolved into the
processes with which we are familiar today. Sugar coating pans have changed
little in the last one hundred years. Copper pans, a leftover from confections,
have been replaced by stainless steel. The source of drying air has progressed
from charcoal fires (4) to steam and finally, the forced hot air systems in use
today. Lastly, the coaler's ladle has been replaced by a spray nozzle to better
control the application of coating solutions.

While the art of sugar coating had reached near perfection in the early
1950's its shortcomings (9) would lead to its overshadowing by a more efficient
and versatile technology. The introduction of film coating (Abbott Laboratories,
1953) to the pharmaceutical industry allowed for great changes in the way
formulators perceived tablets.

(

No longer were they bound to the use of

featureless, nearly spherical tablets as the newer polymeric coatings allowed for
tablets of many shapes. Even embossed tablets could be coated in an efficient
and aesthetically pleasing manner.

These new coatings although versatile,

were not well suited for use in existing coating equipment. At about the same
time as the development of the new polymeric coatings, two advances in
coating technology were introduced. Both of which have become essential to
the modern pharmaceutical industry.

The addition of many small holes and it's enclosure within a sealed
cabinet were modifications of the conventional coating pan which led to the
"perforated" pan. Perforated pans (i.e. Thomas Engineering's Accela Coater
and others) allow for the passage of great volumes of air across the tablet bed
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and controlled temperatures which are necessary to meet the demands of
polymeric film coatings.

The second of these innovations, the air suspension coater was an
entirely different approach to coating (10). Unlike coating pans, the mechanics
of the suspension coater caused tablets to continually rise and fall in a stream
of gas while the coating solution is sprayed onto them from below. Since it's
inception, the "fluid bed" coater has undergone continual modification leading to
a very versatile tool capable of coating tablets, pellets, and even very small
granules in a timely fashion .

While capable of many things, perhaps the

greatest advantage of this apparatus lies in its ability to function in a "closed
loop" thereby facilitating the recovery of organic solvents and increasing the
level of occupational and environmental safety.

(
Further advances in coating technology have been less monumental yet
have served to enhance the existing technology.

After all, the coating

machinery and methods most commonly employed are well suited to the types
of coating that is performed in today's industry. Likewise, progress in coating
machinery will most likely accompany, or follow, the development of new types
of coatings. Unfortunately, this is the age of cost containment and conservative
formulation strategies within the industry.

The chance of an entirely new

approach to tablet coating coming into large scale usage in the near future is
rather small unless it proves vastly superior to existing methods.

SUSTAINED RELEASE COATINGS: A HISTORICAL SURVEY

12
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In the preceding section , an attempt was made to provide the reader with
an overview of the methods and technologies employed in the coating of solid
dosage forms during the past century. The majority of the methods described
were simple, developed by pharmacists for use within the pharmacy, primarily
for the purpose of making distasteful drugs more palatable.

Later, coating

would evolve into a science which allowed the formulator to selectively alter, or
improve, the biopharmaceutical behavior of the products to which they were
applied.

Although there are many ways to obtain the sustained release of
medication (11 , 12), coatings applied to tablets, pellets, or granules are perhaps
the most popular.

According to USP XXll (13) there are three classes of

coating commonly employed in the manufacture of solid dosage forms. The
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oldest of these, the "Plain Coatings" (USP XXll), are those used to alter the
taste and appearance of tablets or to protect them from the detrimental effects
light and moisture.

Plain coatings, perhaps best exemplified by sugar and

hydroxypropylmethylcellulose, are not intended to alter the biopharmaceutical
performance of the drug contained within them . The second group of coatings,
dubbed "Delayed Release" by USP, are more commonly known as "enteric".
The enteric coatings (i.e. cellulose acetate phthalate), due to their poor solubility
in acidic media, serve to protect acid labile drugs from the low pH of the
stomach by delaying their release until the tablet has reached the intestinal
tract. Sustained release coatings ("extended-release" USP XXll), those which
have been designed to meter the amount of drug released from a dosage form ,
complete the list.

13

Until this point, the discussion of sustained release film coatings has
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been oversimplified, implying that the coating is a single, pure entity. Rather,
film coatings are a mixture of several components which result in a continuous
film with desirable properties. Generally, a film coating solution will contain four
basic components; film former, solvent, plasticizer, and colorant (3 ).

These

components, both alone and in conjunction with one another have been the
subject of numerous studies and several lengthy reviews . While not the focus
of this paper, general reviews of film coating have been presented by Banker
(14), Conrad and Robinson (15), and Seitz et al. (1 ).

Pharmaceutical film coatings is a broad terminology which encompasses
several types of film . These films modify the release of medicaments via three
basic

(

mechanisms;

erosion

(polyethylene

glycol},

(hydroxyethylcellulose) and diffusion (ethylcellulose).

gel

formation

Those coatings which

provide release through diffusion have a reputation of being predictable, easy to
apply and are probably the most common sustained release coatings employed
today.

Yet the majority of today's sustained release coatings are ones, or

descendants of ones, first used in the 1950's. Generally, the evolutionary path
of these coatings began with polymers dissolved in organic solvents. Later, in
response to many factors , attempts were made to prepare entirely or partially
aqueous coating solutions.

Throughout the past forty years other coating

techniques have also been attempted, none of which has received the
acceptance of coating from solution.

The vast body of literature published on the subject of coating would lead
an

investigator to

believe

that

there
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are

hundreds

of coatings

and

(

methodologies employed today.

A closer examination reveals the contrary.

The current United States Pharmacopeia only lists three sustained release
coatings that function as a rate controlling membrane; cellulose acetate,
ethylcellulose, and methacrylic acid copolymer. Although other coatings exist,
these three remain the most popular, undergoing continual modification to
withstand the challenges of time and changing regulatory climates.

As the

previous sentence suggests, the evolution of sustained release coatings was
not one that was purely driven by the quest for better performance.

Other

issues, including safety (occupational and environmental) and cost have played
an equally important role in the development of suitable coatings.

At the time film coating was introduced to the marketplace (Abbott
Laboratories 1953) researchers were searching for economical and more

(

versatile alternatives to sugar coating (9). The use of polymeric film formers in
conjunction with organic solvents was perhaps the most important advance in
dosage form development of that era. Their introduction provided researchers
with new avenues to explore in the quest for controlled drug delivery and has
led to the invention of many of the technologies which are so important today.

Many of the early commentaries touted the benefits of organo-soluble
polymers as coating agents while they remained quite apprehensive about the
use of aqueous solutions (9, 17). The fear of dilute aqueous solutions was
largely based on experience gained from sugar coating where the high water
contents of coating solutions were implicated as the cause of stability problems
and long processing times. The principle benefits of solvent usage were the
considerable reduction in processing times and the removal of water from the
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process, thereby reducing the loss of active ingredient through hydrolysis. Yet
another advantage of organic solvents was their ability to completely dissolve
the polymeric film formers thereby allowing for smooth, continuous coatings
which were capable of protecting medicaments from environmental stresses
and making tablets more distinctive.

An early patent for a sustained release tablet is recognized as the first to
make use of a polymeric membrane to control the release rate of a drug
substance.

Assigned to Consolazio in 1949 (US patent # 2,478,182), this

patent described the manufacture of a tablet composed of granules of sodium
chloride coated with cellulose acetate or cellulose nitrate that was designed to
eliminate the gastrointestinal upset caused by the localized deposition of
medicaments.. Consolazio claimed that the invention delayed the solution time

(

of sodium chloride some 60 to 80 minutes by the gradual leaching of drug
through and the subsequent bursting of the cellulosic membrane (11 ).
Unbeknownst to Consolazio at the time, was the semipermeable nature of
cellulose acetate. His results might have been quite different if a larger organic
molecule had been used since, due to their size, many drugs will not pass
through cellulose acetate membranes. Although larger organic molecules are
retained , water will still enter the tablet leading to the eventual bursting of the
membrane and subsequent "dumping" of the medication within.

A similar

approach to sustained release was undertaken by Rosenthal (US patent #
2,895,880 issued 1959) that substituted any one of a number of prolamines for
cellulose acetate. The principal difference between this approach and that of
Consolazio was the digestibility of prolamines which would ensure the release
of medication into the GI tract.
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By 1958 ethylcellulose had joined cellulose acetate as a polymeric
membrane for sustained release .

A patent issued to Lowey (US patent

2,853,420) made use of granules of an inert material that were coated with a
solution of ethylcellulose and drug. Once ingested, the drug entrapped within
the ethylcellulose membrane would slowly diffuse out from the membrane and
be absorbed. Knowledge of the mechanics of diffusion allowed the release rate
to be "programmed" by blending together granules of differing film thicknesses.

It is interesting to note that the three polymers most commonly used
today as sustained release membranes were introduced to the industry before
1962. Cellulose acetate and ethylcellulose, both mentioned previously, were
introduced before 1958.

(

The third polymer (really a class of polymers)

Methacrylic acid copolymer, was first used in a 1961 matrix formulation
patented by Levesques (US patent# 2,987,445). Levesques designed a matrix
tablet which contained drug and soluble pore formers dispersed in a matrix of
polyethylmethylmethacrylate

or

copolymers

of

methylmethacrylate

and

alkylacrylate that allowed for the slow leaching of drug into the gastrointestinal
tract.

The fact that only three polymers which provide sustained release
through membrane diffusion are listed in USP should not be construed as a lack
of research in this area. Several researchers of the 1960's sought to find other
polymeric materials that would exhibit suitable sustained release properties (18,
19, 20, 21 ). Much of their work was focused on various combinations of other
vinyl , acrylic, and cellulosic polymers and provided a battery of screening tests
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by which the suitability of a candidate polymer system could be judged.
However, what these studies had failed to do was develop a new organosoluble coating system which would be widely accepted by the industry.
Possible reasons for this are many but perhaps the two most significant ones
are the risks associated with organic solvent usage and the emergence of a
newer hybrid technology, the pseudolatex coating.

Near the end of sixties, new, improved methacraylate derivatives had
been introduced to the industry for use as diffusion controlled membranes (22).
Although they performed well , these copolymer systems represented the end of
an evolutionary pathway. Stricter environmental legislation in conjunction with
the high cost of controlling organic solvent emissions forced researchers to find
alternative, "environmentally friendly" coating systems.

(

An early, and now

widely known , product of this search was the pseudolatex dispersion.

Research has shown that pseudolatex dispersions, finely divided
colloidal dispersions of water insoluble polymers in aqueous media, can be
prepared from many water insoluble polymers.

These preparations possess

several properties which made them the most popular possible replacements
for organic solvent based coatings including; no need for organic solvents, high
solids concentration with low viscosity, shorter drying times through increased
solids concentration, and lower water vapor permeability than comparable films
from organic solution (23).

The use of latex dispersions invivo could be traced back to their listing in
the U.S. Federal Register (1961) as a food additive (23). Later, after perfecting
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acrylate pseudolatexes for other pharmaceutical coatings, at least two
researchers had developed systems which would provide diffusion controlled
drug release (24, 25). The commercial acceptance of acrylate pseudolatexes
for diffusion controlled membranes (Eudragit (26)) led to the development of
ethylcellulose pseudolatexes (Aquacoat (27) and Surelease (28)) and more
recently , those made form cellulose acetate (FMC corporation (27)) .

Pseudolatex technology has received such considerable attention from
both academic and industrial researchers that an in depth discussion would be
redundant and beyond the scope of this paper. If interested in the science and
application of these coatings the reader should start by consulting the chapters
by Lehman and Steurnagel in Aqueous Polymeric Coatings for Pharmaceutical

Dosage Forms (22,23) as they provide comprehensive reviews of the subject.

(
While the pseudolatex coatings mentioned previously have been proven
effective in many pharmaceutical applications, one somewhat disturbing fact
remains.

The extensive research on, and the wide acceptance of this

technology is a largely due to the fact that the same three, well accepted
polymers which had been historically used for sustained release were used in a
new manner.

In fact, it is only recently that another, completely different

polymer has begun to gain acceptance. In 1989 Li and Peck (29) introduced
sustained release tablets that were coated with a silicone elastomer latex (Dow
Chemical (30)) . Although it was yet another latex type coating, the use of a
silicone elastomer represented a departure from the use of methacrylate and
cellulosic polymers.
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Unlike the existing latexes, those made of silicone are completely
impermeable to water and require the use of a pore forming agent, usually
polyethylene glycol, and an anti-tack agent, fumed silica.

The amount of

polyethylene glycol in the film ultimately determines its porosity and subsequent
drug release rate . Li and Peck demonstrated the ability of silicone elastomers
to provide the apparent zero order release of potassium chloride from coated
tablets for greater than 12 hours with 20 percent PEG 8000 (29).

Faster

release could be gained by increasing the percentage of PEG. Other factors
which were believed to have an effect on the release rate from silicone
elastomer films include; the weight of coating applied, heat treatment and pH of
the dissolution media have been confirmed by Dahl and Sue (31)

The silicone elastomer latex represents an adaptation of existing

(

pharmaceutical technology to a new type of polymer.

Although not yet

approved for use in pharmaceutical formulations , silicone elastomers are used
for medical applications and are a representative of a trend which has
developed within the industry. The manufacturers of pharmaceutical excipients
are well aware of the difficulties that are encountered when new excipients are
submitted for FDA approval.

The fact that only three polymers that provide

diffusion controlled sustained release are listed in the Pharmacopeia is due, not
to a lack of research , but due to the difficulty with which a prospective polymer
would gain approval. It seems that contemporary research has taken this into
consideration and has focussed it's effort on materials which are already
approved for invivo usage.
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Recent studies of sustained release film formers appear to be embarking
on yet another major trend in pharmaceutical coating.

Remember that

sustained release coatings began as organic solutions and evolved to aqueous
dispersions in response to changing safety and environmental regulations .
Much of the sustained release film research during the 60's and ?O's was
centered on updating the polymers which had been used previously with a few
noteworthy exceptions.

One of these attempts was is described in a patent issued to Seiyaku in
1967 (British patent #1 ,075,404) which described the "electrostatic" coating of
tablets. In its truest form , electrostatic coating allows for the deposition of thin
polymeric films without the need for any solvent.

Films are formed when a

charged particle is attracted to a substrate of opposite charge.

Seiyaku's

invention was not really a true electrostatic coating as it still required the use of
a solvent which had to be removed after coating (32). Another earlier attempt
by Endicott and later marketed by Abbott as "Gradumet" is a forerunner of some
of the more interesting attempts of recent years (11 ). The Gradumet was a
matrix tablet composed of drug and a plastic carrier which , after manufacture,
was exposed to acetone vapors causing a the plastic to coalesce into a
continuous network. The coalesced plastic provided a tortuous matrix which
delayed the release of the drug held within it.

Recent studies of sustained release coatings appear to be branching out
onto two pathways. While some determined researchers are experimenting
with polymeric materials which have not yet gained FDA approval, others are
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looking at ways to modify other preapproved polymers to provide sustained
release membranes.

Perhaps the most promising attempt to make use of an already approved
polymer lies in the crosslinking of alginic acid salts. The sodium salt of alginic
acid is a hydrophillic, water soluble polymer which has traditionally been used in
tablet manufacture as a binder and disintegrant.

On the other hand, the

calcium salt, although hydrophillic, is insoluble in water. Julian and colleagues
studied the ability of free films of calcium alginate to control the release rate of
drugs (33).

Later, several researchers studied coating methods which

converted sodium alginate to calcium alginate on the surface of the tablet or
pellet (34,35). Bhagat et. al. describe a method in which guiafenisen tablets
containing calcium chloride are dipped into a solution of sodium alginate.

(

Immediately after immersion, insoluble calcium alginate begins to form on the
tablet surface. Throughout the immersion calcium chloride , and unfortunately
some drug, leach out of the calcium alginate membrane thereby maintaining the
conversion of polymer at the surface. The thickness of the coating is controlled
by the time of immersion in the sodium alginate solution. Through the use of
this method Bhagat was able to produce tablets with an approximate film
thickness of 2 mm that were able to provide the sustained release of
guiafenesin for four hours. This technique, although promising, is not without its
shortcomings. Perhaps the most difficult of these are the Joss of drug during
film formation and the rather thick films required for reasonable release rates .

Abletshauser and co-workers , dissatisfied with the immersion method
used by Bhagat, adapted the sodium to calcium alginate crosslinking process
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for use in a fluid bed coater (35) .

In their study pellets of indomethcin and

acetaminophen were coated in a specially modified fluid bed that contained two
spray guns.

One gun sprayed a sodium alginate solution, whi le the other

sprayed calcium chloride in alternating cycles. Drug release from these pellets
with a 100 micron thick coating was extended over periods of three and eight
hours for acetaminophen and indomethacin respectively. Although this method
elim inated the drug loss of Bhagat's technique, it required considerable
processing times due to the large amount of water in the coating solutions.

While aqueous coatings have eliminated many of the problems found in
solvent coating, the removal of water remains a problem.

Some recent

attempts at novel sustained release coating have sought to develop systems
which do not require any solvent.

(

Yoshida and co-workers reported the

sustained release of potassium chloride from beads of gamma radiation
crosslinked methacrylates (36). The production of the beads was accomplished
by dropping a liquid mixture of drug and monomer into an extremely cold
quenching bath and then exposing the frozen globules to gamma rays . The
extent of crosslinking was so complete and impermeable that the addition of
PEG 600 was necessary to facilitate diffusion.

A similar approach to coating is currently under study by Wang and
Bogner who have been experimenting with the photocrosslinking of several
siloxane prepolymers (37,38). Unlike that of Yoshida , their method employs the
use of high intensity UV light in conjunction with a suitable photoinitiator
(Benzoin Methyl Ether) that has been adapted for use in a flu id bed coater.
With in the coater, the liquid prepolymer and photocatalyst can be sprayed onto
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pellets and exposed to the UV light. Upon exposure to the UV light the polymer
will begin to crossl ink, thereby increasing in viscosity until a solid, insoluble
coating is obtained.

Radiation crosslinking offers a novel and economical way to produce
sustained release coatings in the future .

Unfortunately, current academic

research must overcome several problems if it is to be accepted for invivo
usage in the future.

Firstly, both of the radiation crosslinked methods

mentioned previously make use of prepolymeric monomers which pose serious
health risks if they remain unpolymerized. Additionally, some of the methods
require catalysts which may also prove toxic. Still another possible problem lies
in use of rad iation as an energy source. Remember that ultraviolet light has
long been known as a cause of drug degradation. Yet, if a system can be

(

developed which makes use of materials which are approved, or approvable, for
invivo

usage

it will

open

up

many

new

opportunities

for

improved

pharmaceutical coatings.

CONCLUSIONS

Coating, in one form or another, remains an integral part of the
pharmaceutical industry. Yet to fully understand its future , investigators must
be aware of the vast body of work which precedes them and make use of the
information contained within it.

The past forty years have provided the

pharmaceutical industry with several lessons which have been, and will remain
valuable.

While it is true that the equipment and materials used in the

manufacture of coated, sustained release dosage forms has not changed
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drastically in the last forty years , it has evolved. Countless materials have been
screened for use as release rate controlling membranes yet, until recently only
three have been widely used.

The same three polymers which were once

deposited from organic solution, have been continually updated to comply with
ever changing pharmaceutical, safety, and environmental regulations .

As researchers continue to develop new types of sustained release
coatings, they must remember that those which have been successful in the
past have been so, not only due to their performance, but also because of their
prior approval for invivo usage.

Future investigators should not regard this

observation as a warning to avoid new, unapproved materials. Rather, it should
serve to impress upon them the realities of the pharmaceutical industry. While
there have been many good ideas, greater attention should be given to those
systems which are ultimately approvable.
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HYPOTHESIS TESTED HEREIN

It should be possible to develop an entirely water soluble polymeric coating
system for solid, pharmaceutical dosage forms , which will provide adequate
dissolution control and have the potential for commercial application, when
such a system is produced via controlled exposure to radiation .

(
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SPECIFIC OBJECTIVES of RESEARCH

I.

Search literature for:
a.

Polymers that may be crosslinkable and have been
demonstrated to be safe for usage in vivo.

b.

Prior examples of radiation induced crosslinking in
pharmaceutical preparations.

II.

Evaluate the potential of rad iation induced crosslinking in the
manufacture of pharmaceutical dosage forms .

Ill.

Explore the nature of radiation induced crosslinking of
hydroxyethylcellulose under different experimental conditions

(

(radiation source, molecular weight of polymer, catalyst
concentration, etc.).
IV.
V.

Examine the effect of crosslinked films on drug dissolution control.
Explore the possible physico - chemical changes which
hydroxyethylcellulose may undergo as a result of the crosslinking
conditions selected.
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SECTION II

(

Manuscript II "Photocrosslinked Hydroxyethylcellulose Membranes as
Sustained Release Coatings: A Feasibility Study."

Manuscript Ill "Photocrosslinked Hydroxyethylcellulose Membranes
as Sustained Release Coatings: Assessment of Performance In
Vitro ."

Manuscript IV "Photocrosslinked Hydroxyethylcellulose Membranes
as Sustained Release Coatings: Problems Associated with and
Possible Solutions for the Characterization of Crosslinked Materials."

Primary conclusions drawn from this investigation.

(
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Manuscript II

(

PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES
AS SUSTAINED RELEASE COATINGS : A FEASIBILITY STUDY

(
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PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE
MEMBRANES AS SUSTAINED RELEASE COATINGS: A FEASIBILITY STUDY

ABSTRACT
Photocrosslinkable films which provide prolonged drug release have been
developed as possible alternatives to traditional organo - soluble polymeric
coatings. Unfortunately, the utility of many of these systems may never be
realized due to concerns over the in vivo safety of one or more of their
components. This study explores the feasibility of producing photocrosslinkable
films that lessen or eliminate safety concerns through the use materials which
have prior approval for use in pharmaceutical preparations. Through the careful
selection of polymer and photocatalyst, films have been produced that readily
crosslink upon exposure to an appropriate light source. Once crosslinked the
polymer, hydroxyethylcellulose, is no longer readily soluble in aqueous media.
Possible advantages of this system as a possible pharmaceutical coating , lie in
the regulatory acceptance of each of its components and its ability to crosslink
when exposed to visible light.
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Hydroxyethylcellulose, Riboflavin 5' phosphate, Photocrosslinked, Sustained
Release, Sustained Release Coating, Visible Light, Ultraviolet Light
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INTRODUCTION

The introduction of the sustained release (SR) coating to solid dosage
form manufacture during the 1950's had revolutionized oral drug delivery and
opened up many new research paths for pharmaceutical scientists. A review of
the coating literature might lead contemporary formulators to believe that there
are dozens of different sustained release coatings at their disposal. Closer
examination reveals that nearly all of the coatings in use today have been
derived from one of three, time tested polymers (cellulose acetate,
ethylcellulose, and methacrylic acid copolymer) that have been in use since the
1950's.
The reasons why today, some forty years since the introduction of

(

sustained release coatings only three polymers have been widely accepted,
surely cannot be blamed on a lack of research . Since the 1950's, many authors
have published studies which sought additional polymers that could meet this
need (1-5). While they were successful in their searches, their candidates were
nonetheless unacceptable for in vivo use. The failure of so many of those early,
second generation polymers to gain acceptance by regulatory bodies may be
summed up by one word , safety.
The safety of cellulose acetate, ethylcellulose, and methacrylic acid had
been proven by many years of use prior to the adoption of strict safety
legislation. Because of increased concerns over product safety, many possible
successors to the aforementioned polymers did not, nor likely ever would , gain
such approval.
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While the concern over safety in vivo remained an important criteria to
judge possible SR coatings, the heightened environmental awareness of the
1970's introduced additional criteria which played an equally important role in
their fate . Prior to the 1970's most SR coatings were applied from organic
solutions providing for elegant and effective coatings that were both easy and
economical to apply. Economical, until The Clean Air Act of 1970 and the
increased awareness of the health risks associated with prolonged organic
solvent exposure placed restrictions on their use (6).
During the late 1960's aqueous derivatives of the traditional organic
solvent coatings were developed with the hope that they might someday
eliminate the need for the organic solvents (7). Although these pseudolatex
coatings have proven useful, they too have limitations. Consequently, the
search for new coatings continues with much of the effort being spent on

(

alternate formulations of the same three, time tested polymers. While it makes
sense to try to modify extant techniques, there are always alternative
techniques which should be investigated.
One possible avenue of investigation is the insolubilization of water
soluble cellulose derivatives with a suitable crosslinking agent (i.e.
divinylsulphone, dimethylurea and glyoxal) (8-10). The application of such
technology to pharmaceuticals appears quite feasible at first. However, the
toxic potential of the crosslinking agents and the harsh conditions required for
their reaction makes the use of these techniques nearly impossible in
pharmaceutical manufacturing, unless a less destructive, less toxic system can
be developed.
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Uehara and Sakata report that hydroxyethylcellulose (HEC) may be
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rendered insoluble, without the use of an external crosslinker, by exposing the
polymer to a gas plasma (corona treatment) (11 ). Other researchers have
reported the insolubilization of cellulose ethers by exposure to ultraviolet light in
the presence of a photosensitizer (i.e. chrome or azo dyes) (12). While several
azo dyes are approved as colorants for pharmaceuticals, many are under
scrutiny by regulatory agencies and their future as pharmaceutical excipients is
in question.
This paper seeks to determine the feasibility of producing a purely
aqueous sustained release coating, containing a polymer and photocatalyst that
may be deposited, by conventional means, onto the surface of a tablet and
rendered water insoluble by exposure to light. While others have attempted
similar radiation crosslinked coatings (13, 14), their methods are such that the

(

source of radiation may cause extensive drug degradation or pose serious
health risks due to the toxicities of the photocatalysts or monomers employed
(15).

It should be possible to circumvent the shortcomings of the
aforementioned radiation cured coatings through the careful selection of coating
components. The system discussed in this paper has been prepared entirely
from FDA approved components and employs an insolubilizing technique which
is less likely to be detrimental to the dosage form .

MATERIALS AND METHODS
Materials

Natrosol 250 L, M, and H pharmaceutical grade hydroxyethylcellulose
was provided by the Aqualon Corporation (Wilmington, DE). The viscosity
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averaged molecular weights of the different grades of polymer were reported
(by the manufacturer) to be 90,000, 720,000 and 1,000,000. Riboflavin and
Riboflavin-5'-phosphate sodium were purchased from Sigma Chemical (St.
Louis, MO) while FD&C Red #3, FD&C Red #40, FD&C Blue #1 , FD&C Blue #2,
FD&C Green #3, FD&C Yellow #5 and FD&C Yellow #6 were provided by
Warner Jenkinson (St. Louis, MO). Methanol, Urea, Acetone , HCI (0.1N) and
NaOH (0.1 N) were purchased from Fisher Scientific (Springfield, NJ).
Simulated Gastric Fluid with enzyme was prepared as per USP XXll.

Screening of Possible Catalysts
Hydroxyethylcellulose is readily water soluble when its molecular weight
is less than 1.3 x 106. Therefore, films prepared for this study were expected to
be readily soluble unless some degree of crosslinking had occurred .
For the initial photocatalyst screening studies, aqueous solutions of each
candidate dye (6 mg/ml) were prepared. A 1.0 ml aliquot of each dye was
added to 9.0 ml of a 3.0 % Wfw solution of Natrosol 250 L (90,000 mw) and
mixed thoroughly yielding a final dye concentration of (0.6 mg/ml). A small
amount of each solution was then poured onto individual glass plates, spread to
a thickness of 12 mils (0.305 mm) and subsequently dried at 5ooc resulting in a
film with a 2.0 % dye concentration based on total solids content.
After drying the films were placed on to a conveyor belt moving at 30 feet
per minute and exposed to 600 watts of ultraviolet light from two mercury arc
lamps placed six inches overhead. The amount of UV exposure was controlled
by limiting the number of times which a sample film was passed under the light
source at a speed of 2 seconds per pass. Samples were exposed for 0, 3, 6, or
9 passes. Following UV exposure, equal amounts of exposed and control films
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were stripped from their glass substrates and placed into 20 ml of water and
shaken vigorously. After one hour of mixing, the samples were compared
amongst one another. A qualitative comparison was used to determine which
dye produced the most insoluble HEC.

Determination of Optimum Polymer - Photocatalyst Ratios

Experimental Design
In order to determine the optimum combination of polymer, catalyst and
light exposure, a 2x3x6 full factorial design with three replicates was used. In
the original design, each of the two different grades of polymer designated M
and H were to be combined with six concentrations of catalyst (0,2,4,6,8 and
10% w1w based on weight of polymer) and three levels of ultraviolet light
exposure (0, 5 and 10 passes under UV lamp at a speed of 2 sec./pass).
After the preceding study had been completed, further experimentation
revealed that visible light may, in fact provide a better yield of insoluble material
than UV light. Consequently, a new study with 2 polymer grades (M and H), 3
levels of visible light exposure (0, 24 and 120 hours}, 3 levels of catalyst (0, 2,
and 4% Wlw based on weight of polymer), and three replicates was performed.
The number of catalyst concentrations had been reduced after studying
preliminary data from the ultraviolet light study.
Data from each study was fitted to an analysis of variance model using
PROC GLM on the SAS statistical software (Release 5.18, SAS Institute Inc.,
Cary, NC). All factors and all possible interactions were considered.

Preparation of Films
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Stock solutions of HEC , M & H grade, were prepared by incorporating 9.0
g of polymer into 542.5 g distilled water with the aid of a homogenizer (Silverson
L4R UK) run at low speed. After preparation the stock solutions were kept in a
dark refrigerator and allowed to deaerate. The solutions were prepared so that
a 90 ml aliquot would yield a final polymer concentration of 1.5 % W/w when
brought up to a volume of 100ml with one of several riboflavin-5'-phosphate
solutions.
To obtain the necessary concentrations of riboflavin-5'-phosphate , a 15
mg/ml stock solution of the catalyst was prepared and protected from light.
Aliquots of 0, 2, 4, 6, 8, and 10 ml of the riboflavin-5'-phosphate stock solution
were then pipetted into 10 ml volumetric flasks and brought to volume with
distilled water. The diluted riboflavin solutions were then added to the 90 ml
aliquots of the polymer, thoroughly mixed, and allowed to deaerate in a
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darkened refrigerator.
Prior to film casting, the solutions were warmed to room temperature and
divided into three equal portions. The portions were then individually poured
onto preheated (600C ) plates of untreated window glass (4 x 8 inches) and
spread into thin films with the aid of a film casting table (RK Print-Coat
Instruments, UK) equipped with a# 8 casting rod . The wet film thickness was
0.040 inch (1.016 mm). After casting the films were dried in a darkened 6ooc
oven for 24 hours, removed and then stored in darkness until needed.
Later, the dried films were exposed to either visible or UV light to initiate
the "crosslinking" reaction . Films kept in darkness were used as controls
through the study. Ultraviolet light exposure was provided by a Fusion Systems
(Rockville, Md) F300-6 electrodeless UV curing system equipped with a
mercury "H" bulb and a conveyor belt operating at 30 feet per minute. The
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amount of UV exposure was controlled by the number of times (0, 5 &10 at a
speed of 2 sec./pass) that the plates were passed under the UV lamp. Visible
light exposure was accomplished with the aid of a Hotpack environmental
chamber (model 352642, 600 ft. can ., 25°C). Films were exposed to the
lamps for either one or five days and immediately tested upon removal from the
chamber.

Percent Insoluble Determination
The amount of insoluble material was determined by a method adapted
from that of Geurden (9). A sample of each film was stripped from the glass
substrate and accurately weighed (approximately 150 to 250 mg per sample).
The weighed samples were then placed into 100 ml of distilled water and stirred
for two hours. After stirring the samples were decanted into a fritted glass
funnel containing a piece of pre-dried, pre-tared filter paper (Whatman #2) and
rinsed with 200 mis of distilled water. Excess solvent was removed by vacuum
filtration and the samples were dried for 24 hours at 65 oc. Samples were
removed from the oven and immediately weighed. The percentage of insoluble
HEC was determined by the following equation: (weight of paper & soaked film weight of paper)! initial weight of film x 100. Each solvenUfilm combination was
repeated in triplicate.

Solubility Evaluation
The solubilities of control and visible light exposed films were evaluated
in several different solvents in an attempt to understand the changes , if any,
that the HEC molecule undergoes as a result of the insolubilizing procedure.
Additionally, several of the test solvents were chosen so that a prediction could
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be made as to how the crosslinked films would withstand the rigors of the
gastrointestinal tract.
Films were prepared from a solution containing 1.5 % W/w
hydroxyethylcellulose, 0.03 % W/w Riboflavin-5'-phosphate, and 98.47 %
distilled water which was prepared in a manner that was consistent with
previous film casting solutions. The solution was then stored in a dark
refrigerator until needed.
Films were cast in a manner that was consistent with the procedure
mentioned previously. Immediately after casting, the wet films were transferred
to a dark oven and dried, overnight at 55oc . Once dry, the films were divided
into two groups, one kept in darkness and the other in a lighted stability cabinet
(Forma Scientific model 3890, 1000 ft. can ., 250C) for seven days.
Afterwards , 2.5 x 4.0 cm pieces of each of the films were cut with a razor
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blade, removed from the glass plates and accurately weighed (approximately 50
mg/piece). After weighing , the film samples were transferred to an erhlenmeyer
flask containing 100 m L of either of the following solvents; distilled water, 0.1 N
HCI, 0.1N NaOH , Acetone , Urea (10 % aqueous), Methanol and Simulated
Gastric Fluid with Enzyme USP. The flasks were immediately sealed and
shaken gently for 24 hours. Later, the samples were decanted into a fritted
glass funnel containing a piece of pre-dried, pre-tared filter paper (Whatman #2)
and dried for an additional 24 hours. Once dry, the remaining film and filter
paper were quickly weighed. The percent of insoluble film was determined by
the following equation; (weight of paper & soaked film - weight of paper)/ initial
weight of film x 100. Each solvenUfilm combination was repeated in triplicate.

Microscopic Analysis of Film Samples
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Microscopic analysis was used to determine if any gross physical
changes to the surfaces of the HEC films were evident as a result of the UV or
visible light exposure, as surface changes may be indicative of destruction of
the film components. Scanning electron microscopy was used to examine the
surfaces of film samples before and after exposure to UV and visible light
sources (Leica (Cambridge) Stereoscan S-360). Samples were prepared for
study by mounting them onto aluminum SEM stubs with double faced tape and
sputter coating them with gold (Poloron E5100, 1 min. @ 25 Kv).

RESULTS and DISCUSSION
Screening of possible catalysts
Those films which had not been subjected to UV light behaved as
expected, dissolving quickly and completely when immersed in water. A simple
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physical mixture of polymer and dye did appear to decrease the solubility of the
polymer. However, upon exposure to UV light, each of the dye I polymer
combinations produced some amount of insoluble HEC although the amount
was not quantified. Additionally, small amounts of insoluble polymer were
obtained from neat films of HEC which had been exposed to UV light. It is
unlikely however, that these particles were formed through crosslinking rather
their insolubility is more likely a result of UV induced degradation of the
cellulose molecules (16).
Preliminary observation of films which had been immersed in water
proved discouraging as the films , once wet, rapidly disintegrated yielding small
insoluble particulates. However, magnification of the particulate HEC revealed
that the particles were in fact, thin sheets of film which had coiled about
themselves thus forming fibers of different lengths dependent on the dye used.
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The relative length of the fibers was used as an indicator of the integrity of the
film . It, in conjunction with the overall quantity of insoluble material produced
was used to determine the "best" dye for future crosslinking studies.
FD&C Red #40 produced the longest, most continuous fibers of all the
FD&C dyes tested yet, riboflavin , having an apparently greater yield and wide
acceptance as a dietary supplement (vitamin 82) was chosen to be the catalyst
for future investigations. The relatively poor water solubility of riboflavin made it
difficult to produce a transparent, homogeneous film at required catalyst
concentrations. A water soluble derivative, riboflavin-5'-phosphate sodium was
substituted with favorable results .

Determination of Optimum Polymer - Photocatalyst Ratios
The effects of polymer molecular weight, catalyst concentration and light
source are presented in figures 1 - 4. Generally, exposure to light produced
high yields of insoluble material from films containing catalyst, while those films
that had not been exposed or lacked catalyst produced little, if any insoluble
HEC . It should be noted that the apparent production of insoluble HEC in the
films which lacked catalyst or light exposure is largely due to the inherent
viscosity of the polymer. The gelled polymer was retained on the filter during
assay and once dry, did not show evidence of film formation . Also noted was
the tendency of the riboflavin-5'-phosphate to reduce the gelling tendency of
films that had not been exposed to light perhaps due to some degree of acid
hydrolysis (16).
Table 1 lists the p-values for the main effects and all possible interactions
for those films exposed to UV and visible light. Analysis of the data from the UV
study revealed that each of the main effects and their interactions were
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significant at level of 0.05 (ANOVA). However, individual examination of each
polymer grade revealed that the amount of UV exposure and catalyst
concentration were not significant factors for the M grade polymer (p values
0.149 and 0.07 4 respectively) but were clearly significant for the H grade (p
values 0.038 and 0.0004) .
Generally, films of the M grade HEC produced similar amounts of
insoluble polymer, allowing for quite a variation in amount of catalyst and UV
exposure while the yield of the "H" films appeared to be catalyst concentration
dependant. This apparent dependency may be due in part to a decreased
accessibility of reactive functional groups on the HEC molecule due to the larger
molecular size of the "H" grade. If that is the case , the lower intra-sample
variability of the M grade could be explained as its functional groups would be
more readily accessible to the catalyst.

(

The effect of visible light on the HEC - riboflavin-5'-phosphate films was
also studied but on a scale smaller than that of the UV light study. The results
of this investigation are presented in figures 3 and 4. Consistent with the UV
study, films prepared without catalyst tended to form gels that were retained on
the filter paper and erroneously reported as insoluble. Unlike the UV films , the
neat films of HEC exposed to visible light continued to form viscous gels after
prolonged light exposure. However, as in the case of the UV films , the addition
of riboflavin-5'-phosphate suppressed gelling in films that received no light
exposure.
Visible light treatment of the HEC - Riboflavin-5'-phosphate films
produced the highest yield of insoluble material. Statistical analysis of the data
revealed that the grade of polymer chosen and all of the interactions containing
polymer were not significant (see table 1). Figures 3 and 4 show that the
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average percentage of insoluble HEC obtained from films that contained
catalyst and had been exposed to visible light was routinely in excess of eighty
percent and quite reproducible .

Solubility Evaluation
This study was undertaken to gain a general understanding of how
photocrosslinked HEC would behave when exposed to different solvents. Since
the data gathered was not intended to provide an absolute measure of
solubility, the relative solubilities of the films have been graded on a scale of 1
to 1O where 1 represents a solubility less than 10% and 10, a solubility greater
than 90 %. Results are presented in table 2.
Water, HCI, NaOH , and Simulated Gastric Fluid USP were chosen to
simulate conditions encountered in vivo , while acetone and methanol were used
to determine the behavior of the films in organic media. Additionally , the films
were subjected to an aqueous urea solution, as urea is a known decoupler of
hydrogen bonds (11 ). Therefore, a greater solubility in aqueous urea than in
water would be evident of hydrogen bonding and not chemical crosslinking .
The control films were quite soluble in aqueous media, although the
amount of insoluble material obtained from the urea solution was somewhat
greater. While no detectable remnants of film could be found on the filter, it is
possible that some polymer may have been retained within the filter paper
thereby, yielding a slightly higher value for films soaked in the urea solution.
Those uncrosslinked films exposed to organic media remained continuous and
largely insoluble as predicted.
The crosslinking process allowed for great changes in the aqueous
solubility of the HEC films. Films that were freely soluble prior to crosslinking ,
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were poorly soluble afterwards. Values obtained from crosslinked films in water
are consistent with those presented earlier and similar to those of films soaked
in simulated gastric fluid or aqueous urea. Any apparent difference in the
values obtained for the three media in table 2, is small although somewhat
exaggerated since they fall on either side of the 90 % cutoff. Slightly lower
values were obtained for films soaked in HCI and NaOH . These lower values
may be due, in part, to some breakdown of the polymer by acid hydrolysis or
oxidative degradation ( 12).
Finally, there were no great changes in the solubilities of the control and
crosslinked films that were soaked in organic solvents. Any apparent difference
between them in table 2 is somewhat exaggerated due to the actual values
falling on either side of the 90 percent cutoff.

Microscopic Analysis of Film Samples

Representative micrographs of the HEC/riboflavin-S'-phosphate films are
presented in figure S. Figure Sa, depicts a film sample which had not received
any light exposure (control sample). The surface of this film is essentially
smooth and continuous, confirming that it is possible to produce suitable films
with the method employed. Visible light exposure (7 days@ 1000 ft. can.) did
not appear to alter the film surface (Sb). A sample of the film depicted in figure
6 was soaked in water and dried prior to examination (Sc). The micrograph of
the soaked film confirms that the film remained continuous and nearly
indistinguishable from the control, except for the appearance of small
depressions (approx. 20 microns diameter) which do not appear to pass
through the film .
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Figures 5d and 5e depict film samples which had been exposed to
different amounts of UV light (5 and 30 passes, mercury H bulb 600 watts/inch).
The surface of these films appear to have been altered by the UV exposure as
small, somewhat circular, areas of different texture appear. The frequency of
these areas appears to increase with greater amounts of UV exposure.

Conclusions

The ability of light, from both visible and ultraviolet sources, to alter the
aqueous solubility of hydroxyethylcellulose (HEC),irradiated in the presence of a
photosensitive dye, has been demonstrated. While the exact mechanism of the
insolubilization has not been determined, it is believed that the changes in HEC
solubility are a result of crosslinking facilitated by the dyestuff.
Visible light curing of HEC films that include riboflavin-5'-phosphate as
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the photosensitizer offers the most consistent and reproducible method to alter
solubility, however long cure times are necessary. Shorter cure times (minutes
vs. days) are possible when UV light is employed, but the yield of insoluble HEC
is less consistent and the nature of the light source has a greater potential to
cause degradation of the film components.
While there have been other radiation cured coatings, the combination of
HEC and riboflavin is unique in that it exploits the interaction of two compounds
which have prior FDA approval for in vivo usage. Prior approval, although not a
necessity for a prospective new coating, should facilitate its approval provided
that no new, unknown chemical species have been produced as a result of the
photocuring process.
The initial success of this feasibility study warrants further investigation of
photocured HEC/riboflavin-5'-phosphate films as sustained release coatings. It
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is hoped that future studies of photocured HEC films shall demonstrate their
ability to facilitate the prolonged, and consistent release of drugs and other
bioactive molecules which have been coated in this manner.

References

1.

J.W. Kleber, J.F. Nash, and C. Lee, Synthetic Polymers as Potential
Sustained-Release Coatings, J. Pharm . Sci., 53(12), 1519-1521 , (1964).

2.

K.O.R. Lehmann, Acrylic Resin Coating for Drugs, Pharma. International,
3, 34-41 , (1971 ).

3.

L.C . Li and G.E. Peck, Water Based Silicone Elastomer Controlled
Release Tablet Film Coating II - Formulation Considerations and Coating
Evaluation, Drug Dev. Ind. Pharm ., 15(4), 499-531 , (1989).

4.

R.J . Nessel, H.G. DeKay, and G.S. Banker, Evaluation of Polymeric
Materials II Screening of Selected Vinyls and Acrylates as ProlongedAction Coatings, J. Pharm . Sci., 53(7), 790-794, (1964).

5.

V. Venkateswarlu, C.K. Kokate , et. al., Pharmaceutical Investigations of a
Film Forming Material Isolated From Roots of Salacia Macrosperma,
Drug Dev. Ind. Pharm , 19(4), 461-472, (1993).

6.

United States Enviromental Protection Agency, (1970) .

7.

K.O.R. Lehmann, Chemistry and Application Properties of
Polymethacrylate Coating Systems, in "Aqueous Polymeric Coatings for
Pharmaceutical Dosage Forms," J.W.McGinity, eds., Marcel Dekker,
New York, 1989, pp. 153-245.
U. Anbergen and W. Oppermann , Elasticity and Swelling Behaviour of
Chemically Crosslinked Cellulose Ethers in Aqueous Systems, Polymer,
31(10), 1854-1858, (1990).

8.

9.

R.M . Geurden, United States Patent# 3,077,468, (1963).

10. R.M . Geurden, United States Patent# 3,272,640, (1966).
11 . T. Uehara and I. Sakata, Effect of Corona Discharge Treatment on
Hydroxyethylcellulose, Mokuzai Gakkaishi, 36(6), 448-453, (1990).

49

(

12. The Aqualon Company, Natrosol (Hydroxyethylcellulose) Physical and
Chem ical Properties,(1987).
13. R.H . Bogner and J. Wang, Solventless Tablet Film Coatings: Techniques
to Monitor UV Curing , Reprint of Poster from AAPS Annual Meeting,
Poster POD 7132, (1992).
14. M. Yoshida, M. Kumakura, and I. Kaetsu , Drug Entrapment for Controlled
Release in Radiation-Polymerized Beads, J. Pharm . Sci. , 68(5), 628-631 ,
(1979).
15. D.C. Harsh and S.H. Gehrke, Controlling the Swelling Characteristics of
Temperature-Sensitive Cellulose Ether Hydrogels, J. Controlled Release,
17, 175-186, (1991).
16. Cellulose Derivatives, in The Encyclopedia of Chemical Technology, 3rd
ed., M. Grayson ed., J. Wiley and Sons, New York, 1979, pp 118-143.

Acknowledgments

This work was supported by a grant from Ciba - Geigy Pharmaceuticals,

(

Summit, New Jersey. The authors wish to thank Dr. George Lukas and the
entire Pharmaceutical Development Group, of Ciba Pharmaceuticals, Summit,
for their expertise and support. Thanks are also due to Dr. Paul Gallo for his
assistance with the statistical portion of this paper.

50

(
TABLE 1

Statistical analysis of Optimum HEC lnsolubilization Parameters

p - Values

(

Main Effects & Interactions

UV Light

Polymer MW (P)

< 0.001

#Light Exposure (L)
#Catalyst (C)
Pxl
PxC
LxC
Px l xC

< 0.001
< 0.001
< 0.001

.

..
.
.

0.0015 •
< 0.001
0.039 •

Visible Light
0.161
< 0.001
< 0.001

0.867
0.054
< 0.001
0.567

..
.

• denotes significance at 0.05 level
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TABLE 2

Relative solubility of control and visible light cured (7 days@ 1000 footcandles)
HEC films containing riboflavin-5'-phosphate in various solvents. Numerical
values in table denote the average amount of insoluble material obtained from
three separate trials. A value of 1 represents O to 10 % insoluble, 2 represents
11 to 20 %, 3 represents 21 to 30 % etc..

Insolubility of HEC Films
Solvent

(

Unexposed

Exposed

DI Water

10

HCL 0.1 N

9

NaOH 0.1 N
Sim . Gastric
Urea 10% aq.
Acetone
Methanol

8
9
9
10
10

1
2
9
9
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FIGURE 1
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The effect of visible light exposure and riboflavin-5'-phosphate concentration on
the aqueous solubility of films prepared from M grade HEC
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FIGURE 2

The effect of visible light exposure and riboflavin-5'-phosphate concentration on
the aqueous solubility of films prepared from H grade HEC
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FIGURE 3

(

The effect of UV light exposure and riboflavin-5'-phosphate concentration on
the aqueous solubility of films prepared from M grade HEC
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FIGURE 4
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The effect of UV light exposure and riboflavin-5'-phosphate concentration on
the aqueous solubility of films prepared from H grade HEC
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FIGURE 5

(

Scanning electron micrographs depicting surface characteristics of
photocrosslinkable HEC films containing riboflavin-5'-phosphate: (a) Untreated
film , (b) Exposed to visible light (1000 ft. can. x 7 days), (c) Exposed to visible
light (1000 ft. can. x 7 days), soaked in water (24 hrs.) and dried (24 hrs.@ 65
°C), (d) Exposed to UV light (600 watts/in. for 10 seconds), (e) Exposed to UV
light (600 watts/in. for 60 seconds)
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FIGURE 5a
Scanning Electron Micrograph of an Untreated Film
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FIGURE 5 b
Scanning Electron Micrograph of a Film Exposed to Visible Light

(

59

(
FIGURE 5 c
Scanning Electron Micrograph of a Film Exposed to Visible Light
and Washed with Water
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FIGURE Sd
Scanning Electron Micrograph of a Film Exposed to Ultraviolet Light
( 1O Second Exposure)
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FIGURE 5 e
Scanning Electron Micrograph of a Film Exposed to Ultraviolet Light
(60 Second Exposure)
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PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES
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ABSTRACT
A

water

insoluble

hydroxyethylcellulose

(HEC)

when

films

of

containing riboflavin-5'-phosphate

(R5P)

are

membrane

is

obtained

crosslinked via exposure to an appropriate light source.

Unlike other

photocrosslinkable coatings which have been considered for pharmaceutical
applications, the system presented herein is unique in that it is composed
entirely of compendia! materials. Tablets that had been designed to function as
oral osmotic delivery systems when coated with cellulose acetate, containing
either metoprolol fumarate or dextromethorphan HBr, were coated with the
experimental materials. Successful coating of the tablets and crosslinking of the
experimental coatings warranted the determination of drug release rates in vitro.
Dissolution of tablets with crosslinked coatings was less rapid and considerably
better controlled than control tablets whose coatings had not been crosslinked.
The time to 80 percent of tablet label claim released was approximately five
hours for

metoprolol fumarate

and

slightly greater than

3 hours for

dextromethorphan HBr upon successful membrane crosslinking. Comparatively,
uncoated tablets of metoprolol and dextromethorphan each achieved complete
dissolution 1.5 and 0.5 hours, respectively. In both cases dissolution in 0.1 N
HCI was more rapid than in water, yet most of this effect may be attributed to the
increased solubility of the drugs in acid.
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INTRODUCTION
The Clean Air Act of 1970 and recent, more stringent legislation have
made the use of large quantities of organic solvents in manufacturing
prohibitively expensive (1 , 2). As the problems associated with organic solvent
usage have continued to increase, pharmaceutical manufacturers have turned
their attention to the various water based coatings which are currently available.
While the aforementioned coatings offer one possible alternative to those
requiring organic solvents, there are other options currently under development.
Recent research provides examples of what appears to be a new trend in
the development of sustained release solid dosage forms , the in situ
insolubilized coating (3-6). Coatings of this type exploit materials that, once
deposited onto the surface of a dosage form , may be converted into durable,
water insoluble coatings through polymerization and/or crosslinking reactions.
Generally, these coatings may be divided into two groups. The first of
these, as exemplified by Wang and Bogner (7) and Yoshida et. al. (5) relies on
the radiation induced polymerization of monomeric materials to form continuous
water insoluble coatings.

The second , including the methods developed by

Ishikawa et. al.(6) and Abletshauser et. al.(3) exploits the ability of certain
polymeric materials to undergo drastic changes in solubility when crosslinked.
Although each of the aforementioned methods has been demonstrated to
impart sustained release, the possibility of any of them obtaining regulatory
approval is rather limited.
The work of Abletshauser and colleagues may be the exception, as
calcium alginate is currently included in the French Pharmacopeia, a fact which
might facilitate its acceptance elsewhere (8). Nonetheless, it is doubtful that the
alginates are the only GRAS polymers capable of being rendered water
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insoluble in situ. Rather it is quite possible that other polymers which equal, if
not exceed the desired properties of the alginates lie listed in some GRAS list
awaiting our attention.
Previously, we had demonstrated that a practically water insoluble film
could be obtained from water soluble components (HEC/R5P) crosslinked by
exposure to visible light (9, 10). The coating studied herein is similar to others
which rely on changes in solubility of the coating components yet, it is unique in
that it is composed entirely of excipients that are included in the current USP NF
(11 ). An attempt has been made to assess the sustained release potential of
this system when applied to tablets that function as oral osmotic drug delivery
systems. Tablets of this type were chosen for their ability to generate internal
pressures great enough to challenge the mechanical strength of the test
coating, a good measure of a films durability, and the fact that osmotic tablet
coating remains heavily dependent on organo soluble film formers .

Model

drugs were chosen for this study that had different degrees of aqueous
solubility. Metoprolol fumarate is representative of those drugs that are quite
water soluble, while dextromethorphan HBr represents those drugs that are
sparingly soluble.

MATERIALS AND METHODS
Materials
The following materials were obtained from commercial sources and
used without further purification: Natrosol 250 M pharmaceutical grade
hydroxyethylcellulose,

molecular

weight

720,000

(Aqualon

Corporation,

Wilmington, DE), riboflavin-5'-phosphate sodium (Sigma Chemical, St. Louis,
MO), acetonitrile, HPLC grade (EM Science, Gibbstown, NJ), triethylamine (J .T.
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Baker, Phillipsburg, NJ },

hydrochloric acid , acetic acid and

ammonium

hydroxide, all reagent grade (Fisher Scientific, Fairlawn , NJ ), docusate sodium
and ammonium nitrate, all reagent grade (Aldrich Chemical, Milwaukee, WI ).
Additionally,

uncoated

metoprolol

fumarate

(190

mg)

and

dextromethorphan HBr (20 mg) tablets were provided by Ciba - Geigy.
Processing
Coating solution preparation
Tablets were coated with a solution consisting of the following : Natrosol
250M (pharma. grade) 1.5% w/w , riboflavin-5'-phosphate 0.031 % w/w, and
distilled water 98.47%. Both the polymer and riboflavin were dissolved in water
with a propeller mixer (Lightnin' TSR 1516, 1000 rpm) . After several minutes of
mixing, any agglomerated polymer was dispersed with a homogenizer
(Silverson L4R, England) run at a low speed so any untoward effects to the
polymer may be minimized.

Once free of undissolved polymer, the coating

solution was transferred to a darkened refrigerator and allowed to deaerate
overnight. Solutions were warmed to room temperature prior to coating.

Tablet coating
On separate occasions, 1 kilogram of metoprolol fumarate and 1.25
kilograms of dextromethorphan HBr tablets were charged into a Glatt GC 300
coating pan (Glatt AG , Switzerland) and preheated to 45°C.

The following

coating parameters were used throughout the study: pan speed
atom izing air

= 10

rpm ,

= 1.25 bar, inlet air temperature = 55°C , outlet air temperature =

40 - 45°C , air volume 180 m3/hr. The coating solution was delivered to the pan
with a peristaltic pump (Masterflex #7526-00) and sprayed through a 0.8 mm
nozzle tip at an initial rate of four milliliters per minute. Spray rate was gradually
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increased to, and later maintained, at 10 ml per minute.

After a sufficient

amount of the coating solution had been applied, the pan speed was reduced to
5 rpm and the tablets were dried for thirty minutes.

Crosslinking
Once coated, tablets were arranged on clear glass plates and exposed to
600 footcandles of visible light within a Hotpack environmental chamber (model
352642 , 25°C) for three or seven day periods.

Three day exposed

dextromethorphan tablets were exposed to 1000 footcandles of visible light.
Periodically the position and orientation of each tablet, with regard to the lamps,
was changed to ensure complete exposure to the light source.

Once tablets

had been exposed for their prescribed times, they were removed and stored in
darkness in sealed containers.
(

Release Portal
A release portal was drilled in those tablets requiring one with a high
speed mechanical drill (Servo Products Corp. model 7000). Portals were drilled
so that they completely pierced the tablet coating, but did not penetrate the
tablet cores to any significant depth. The portal sizes used for the metoprolol
fumarate and dextromethorphan HBr were: 0.6 and 0.25 mm , respectively.

Dissolution Testing
Metoprolol Fumarate
The release of metoprolol fumarate from HEC/R5P coated tablets was
studied by USP method I (basket), 100 rpm , 900 ml water, 37°C , n

= 6.

The

release rate of metoprolol fumarate in water was determined from tablets in
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various stages of the coating process including: uncoated tablets (n
yet uncrosslinked tablets (n

= 3), coated

= 3), coated

and exposed for three days with and

without a release portal, and coated and exposed for seven days with and
without a release portal.

Additionally, those tablets with crossl inked coatings

were tested in 0.1 N HCI.
One milliliter samples were drawn according to the following regimen : 0,
0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, & 12 hours with an automated dissolution sampling
system (Hanson Research model 75 - 400).

Samples were assayed upon

completion of the dissolution test.

Dextromethorphan HBr
The release of dextromethorphan HBr from HEC/R5P coated tablets was
studied under the same conditions as metoprolol fumarate except the run time
was shortened to eight hours. Samples were drawn according to the following
schedule; 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 6, and 8 hours.

Assay
Metoprolol Fumarate
Interference by riboflavin-5'-phosphate at the analytical wavelength
necessitated the use of HPLC. Consequently, an HPLC method was developed
to separate riboflavin-5'-phosphate from metoprolol fumarate.
system was employed: Column:
Autoinjector:

The following

Shodex RSpack 018 - 613 (15 cm) ,

Waters Wisp 7120 (injection volume: 30 microliters), Pump:

Shimadzu LC10AS (flow rate : 1.0 ml/min. ), Column heater: Eppendorf CH30
(45°C), Detector:

Shimadzu SPD6AV (I 272 nm , 0.02 AUFS) , Integrator:

Waters 840 chromatographic data station.
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A mobile phase consisting of ammonium hydroxide (0.61 % solution)
64.9% w/w, acetonitrile 33.4% and triethylamine 1.7% adjusted to a pH of 11 .0
with acetic acid, was prepared fresh prior to each dissolution run.
The retention time of metoprolol fumarate was approximately 6.1
minutes. The percentage of metoprolol released was determined by comparing
the peak area of the sample to that of the mean peak area of bracketed
standards that represented 190 mg of metoprolol fumarate.

Dextromethorphan HBr
As in the case of metoprolol fumarate, interference by riboflavin-5'phosphate at the analytical wavelength necessitated the use of HPLC.

The

chromatographic system was identical to that mentioned previously except a
Waters Microbondpack C18 column (10m particle size 3.9 x 300 mm) was used
at ambient conditions. Other changes included an analytical wavelength of 280
nm and an injection volume of 50 microliters.
The mobile phase for this assay was prepared in the following manner.
For each liter of mobile phase 700 ml of acetonitrile and 300 ml of distilled water
were combined. Docusate sodium (2.21 g) and Ammonium nitrate (400.3 mg)
were added to the mixture which was subsequently adjusted to a pH of 3.05
with glacial acetic acid, filtered (0.5 micron), and degassed.
The retention time of dextromethorphan HBr was approximately 5.2
minutes at a flow rate of 1.25 ml/min.. The percentage of dextromethorphan
HBr released was calculated by comparing the peak area of the sample to that
of the mean peak area of bracketed standards which represented 20 mg of
dextromethorphan HBr.

71

(

1

Scanning Electron Microscopy
Microscopic analysis of HEC/RSP coated metoprolol fumarate tablets
was used to determine the integrity and continuity of the coating both before
and after dissolution testing. Micrographs of tablets that had been mounted
onto aluminum SEM stubs and subsequently sputter coated with gold (Poloron
E5100, 1 min @ 25Kv) were obtained with a Leica Stereoscan S - 360
scanning electron microscope.

RES ULTS AND DISCUSSION
Background
Throughout this study, tablets that had been coated with the HEC/RSP
and crosslinked were compared to both uncrosslinked tablets and uncoated
core tablets to illustrate the release rate limiting potential of the crosslinked
coating . The time required to attain the release of 80 percent of the tablet label
claim

(T80%},

190

mg

for

metoprolol

fumarate

and

20

mg

for

dextromethorphan, was used as a comparative measure of the dissolution
profiles obtained from the various tablets tested.
Figures 2,3,5 and 6 contain the dissolution profiles of tablets to which a
release portal has been added in order to gain some understanding of the
relative permeability of crosslinked HEC films .

Both the metoprolol and

dextromethorphan tablets used in this study had originally been designed to
function as osmotic delivery systems when coated with cellulose acetate.

In

those systems cellulose acetate acts as a semipermeable membrane allowing
the influx of water and small ions but not larger molecules (drugs) . As water
enters the membrane the internal osmotic pressure rises. The rising pressure
then either causes the rupture of the rigid membrane (undrilled tablet) or
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initiates the "pumping" of drug through the release portal. The bursting of the
undrilled membranes during dissolution testing and a gradual near zero order
release from drilled tablets was assumed to be preliminary evidence of a
semipermeable membrane.

Metoprolol fumarate
Figure 1 compares the dissolution profiles of uncoated metoprolol
fumarate tablets with those that had been coated with the HEC/RSP coating
(approx. 16 mg per tablet) and either exposed to visible light (3 or 7 days at 600
foot candles) or kept in darkness (control). Dissolution of the core tablets (n=3)
was rapid and variable, yielding a T80% of 30 minutes. Complete dissolution
was reached in two hours.
The addition of an HEC/RSP coating to the tablets resulted in prolonged
drug release, regardless of any post coating treatment. Drug release from the
control tablets, although prolonged, yielded a T80% of three hours while those
tablets that had been crosslinked yielded T80%'s of approximately five hours.
Crosslinked tablets, irrespective of the duration of light exposure,
produced the most consistent rate and longest duration of metoprolol fumarate
release (Table 1).

Following a brief lag time (15 min}, the tablets with

crosslinked coatings exhibited near zero order release for nearly four hours. In
comparison , release from the control tablets was less predictable, exhibiting a
longer lag time (30 min) followed by rapid and irregular drug release . Closer
examination of the control tablets shows that their release profile, although
spread out over a longer period, is similar to that of the core tablets.

It is

interesting to note that the release profile of the control tablets is quite similar to
that of the core tablets if the lag time is disregarded. The similarity between
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core and control tablets and the marked difference between their release
profiles and those of the crosslinked tablets may be indicative of two distinct
mechanisms of release.
Clearly, release from the core tablets is dictated by erosion. As the tablet
is wetted, its outermost layers dissolve in the dissolution media thereby
releasing the drug contained within them . This process continues, assuming
sink conditions, until all of the drug has gone into solution. Much the same is
true for the control tablets except drug release is further governed by the
presence of the uncrosslinked HEC/RSP coating. (Remember that HEC is a
hydrophillic water soluble polymer and the 16 mg present on each tablet is
readily soluble in 900 ml of dissolution media.). The lag time exhibited by these
tablets is most probably a result of delayed core wetting due to the hydration of
the HEC coating. Once the coating has hydrated , release from the system is
believed to be determined by a complex mixture of drug release from an
eroding tablet core that is encased within a swollen, progressively dissolving
film . Much of the last ten percent of drug release stems from the delay in tablet
core dissolution affected by the gradual dissolution of the HEC/RSP membrane.
Once the membrane has dissolved, dissolution of the core tablet, previously
delayed by the HEC film, proceeds until the entire tablet dissolves and complete
drug release is obtained.
Unlike the control tablets, those tablets with crosslinked coatings did not
completely dissolve during dissolution testing. Empty, swollen, yet continuous
membranes were recovered from the dissolution vessels after testing of the
crosslinked tablets was completed. Occasionally, these "shells" were recovered
intact but with a tear along one side. Wh ile the coating may have burst during
testing, the low inter-tablet standard deviation obtained from each test of

(
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crosslinked tablets suggests that these tears had either a very small effect on
dissolution rate or, more likely, occurred after the final sample was drawn. The
recovery of the intact crosslinked HEC/RSP shells in conjunction with the rather
consistent release obtained from tablets with crosslinked coatings indicates
membrane controlled diffusion as the principal mechanism of drug release .
Oddly there was little, if any difference in the dissolution profiles of the three and
seven day exposed tablets. This may be indicative of a "crosslinking maximum"
that, once achieved , is not affected by further light exposure.
As mentioned previously, an attempt was made to ascertain the
permeability of the crosslinked HEC/RSP membrane by testing the ability of
drilled tablets to function as osmotic delivery systems. Figure 2 compares the
release profiles of crosslinked HEC coated tablets with those to which a 0.6 mm
release portal had been added. The addition of a release portal served to
increase the average amount of metoprolol fumarate released from three day
exposed tablets by nearly 10 percent.

The release from drilled seven day

exposed tablets was also faster, although the overall difference between tablets
with and without a release portal was not as prominent. This indicates that the
crosslinked HEC/RSP membranes are not semipermeable yet they do serve to
mediate drug release in a controlled and consistent manner.
Lastly, in addition to distilled water, the dissolution rate of crosslinked
tablets (7 day exposure, with and without release portal) was determined in 0.1
N HCI.

Although the insolubility of crosslinked HEC in acid was determined

previously (9), no predictions could be made as to the effects, if any, that the
acidic media might have on drug release from tablets with crosslinked coatings.
The release profiles of tablets tested in water and 0.1 N HCI are presented in
figure 3.
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In each case, the release of drug in water is slower than that in acid.
When dissolution was carried out in acid, the time to T80% ranged from 3.0
hours for tablets with a release portal to 3.75 hours for those without.

By

comparison , drug release from water was slower, yielding a T80% of 5 hours in
each case, although the tablets with a portal appeared to release somewhat
faster in the early part of the dissolution test. This result was not unexpected as
the solubility of metoprolol fumarate is greater in acid (12).

However, the

differences between water and acid are greater than ten percent at the three
and four hour time points. Given the rather narrow standard deviation of the
data, it is possible that the film may be subject to a greater degree of swelling in
acid, thereby facilitating diffusion and a more rapid release of drug.

Dextromethorphan HBr
The dissolution profiles of Dextromethorphan HBr tablets both with and
without an HEC/R5P coating (7.9 mg/tab) and subjected to different amounts of
visible light exposure are presented in figure 4. Initially it was hoped that all
crosslinking could be performed under identical conditions,

however a

malfunction of the 600 footcandle light cabinet necessitated the use of a
substitute lightsource (1000 footcandles) . Due to the different levels of light
exposure, no direct comparison of the three and seven day exposed tablets was
made.
Presented in figure 4 are the dissolution profiles obtained from the
various dextromethorphan tablets tested. As one might predict, based on the
previous discussion of metoprolol dissolution, release from the core tablets was
rapid , yielding a T80% of 15 minutes and complete dissolution within 30
minutes. Likewise, release from the control tablets was prolonged (T80% of
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approx. 1.6 hours), although erratic due to the simultaneous swelling and
salvation of the uncrosslinked HEC/R5P membrane and the tablet core.
Crosslinking of the membrane, as in the case of metoprolol, produced
dextromethorphan tablets which provided rather consistent and considerably
prolonged release over a several hour period. The T80% for the 3 day, 1000
footcandle and 7 day, 600 footcandle exposed tablets were approximately 2.8
and 3.2 hours, respectively . Additionally, near zero order release was obtained
from the 7 day exposed tablets for nearly four hours while that of the three day
exposed tablets continued for nearly three (Table 1).
Figure 5 includes dissolution profiles from dextromethorphan tablets with
crosslinked HEC/R5P membranes tested both with and without a 0.25 mm
release portal. It appears that the addition of a release portal had a very little
effect on the dissolution rate of the dextromethorphan tablets. This observation

)

is further supported by the dissolution profiles presented in figure 6.
A comparison of the dissolution rates of dextromethorphan tablets with
crosslinked HEC/R5P membranes may be found in figure 6. As in the case of
metoprolol fumarate, the release of dextromethorphan was more rapid in acidic
media than in water (T80% of 2.5 hours vs. 3.15 hours).

Yet unlike the

metoprolol tablets, and consistent with the profiles in figure 5, the addition of a
release portal had little effect on the dissolution rate of dextromethorphan in
either media. While no definite explanation of this occurrence is proposed, we
postulate that the portal placed in the dextromethorphan tablets was too small
and thus readily susceptible to blockage by uncrosslinked HEC or other
components of the core tablets.

Electron Microscopy
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Micrographs depicting the surface of the metoprolol fumarate tablets both
before and after dissolution testing in water are presented in figures 7 and 8. In
each figure, micrographs designated "a" represent a tablet photographed prior
to dissolution testing while those designated "b" represent what remains of a
tablet after the completion of testing.
Figure 7 reveals both the disappointing fact that the coating contains
many small holes ranging in diameter from about 0.6 to 0.12 mm . Certainly we
had hoped to form

a continuous membrane and not a microporous one.

Fortunately, observation of the tablets in the dissolution bath revealed that the
shell actually swelled, and maintained a considerable internal pressure during
the course of testing.

It is doubtful that this could have occurred if the film

remained microporous, therefor we postulate that it was possible for the holes
to be sealed, perhaps by a combination of uncrosslinked polymer and swelling
of the crosslinked coating . To some extent this idea is supported by figure 7b
which depicts the remains of a tablet after testing. Drying had caused the shell
to shrink to 80 percent of its original size. Additionally, it appears that the
coating contained a far fewer amount of the large, deeply penetrating holes
(figure 8). At this time it is not known whether the disappearance of the holes is
an actuality or a remnant of the drying process. Irrespective of that fact, when
the tablets are recovered from the dissolution media they are swollen, almost
spherical and able to withhold the osmotic pressure generated by the core
tablet. Clearly, this observation suggests that the holes may not penetrate the
coating entirely, or have been sealed upon hydration.

CONCLUSIONS
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The idea of an in situ crosslinkable tablet coating, made entirely of
materials with current regulatory approval has been realized .

Through

prolonged exposure of prototype HEC/RSP films to visible light we have
demonstrated that an water insoluble film may be obtained from entirely water
soluble starting materials. The practicality of this technology lies in it's use of
conventional coating techniques and a simple, and safe source of radiation .
Although this crosslinking process must still be optimized, this study has shown
that it is indeed possible to obtain consistent and controlled drug release from
tablets that have been coated with crosslinkable HEC.
Indirect evidence has indicated that the crosslinked films in their present
state, do not provide a semipermeable membrane, although membrane
mediated diffusion is the most probable method of release . While not a reality
at this time, a semipermeable membrane might be possible if the coating
process can be optimized to obtain a more continuous and dense coating.
Another option may be the addition of a plasticizer to the system although the
effects of a plasticizer on the "crosslinkability" of the system are not yet known.
While this paper has illustrated the potential of crosslinked HEC/RSP
membranes, the photocrosslinking techniques used herein are somewhat
rudimentary. Obviously if techniques such as this are to become commercially
viable for drug manufacturing , greater effort must be placed

on

the

characterization of the products and processes of crosslinking and the
determination of the mechanism(s) by which the reactions occur.

An

understanding of the physico-chemical nature of this system , in conjunction with
positive, rather than inferred proof of the safety of the crosslinked material could
lead to the regulatory acceptance of this or a similar coating for use in vivo
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thereby offering the industry a class of coatings which behave quite similarly to
organo soluble coat ings but without the need for organic solvents.
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Table 1

Photocross linked HEC/RSP Membrane Dissolution Studies:
PERCENT LABEL CLAIM RELEASED PER HOUR

)

Dextromethorphan HBr
Metoprolol Fumarate
Three Days Seven Days
Three Days Seven Days
Hole
No
Hole
Time Control No
Hole
No
Hole Control No
Hole
Hole
(hours)
Hole
Hole
54.2 30.7 29.6 27.3 29.1
1
8 .7 17.3 25.9 19.5 22 .9
42 .0 29.7 26.7 28.4 28.1
43.9 23 .9 24.6 22 .2 23.1
2
27.2 18.0 16.9 16.2 16.6
4 .3 22.4 21.3 22 .7 22 .7
3
10.2 12.8 11 .5 13.1 10.2
12.2 15.6 16.0 14.1
4
0.7
7.9
6.6
7.8
6.8
6 .8
5.4
3.5
4.5
5
0.7
7.9
6.6
7.8
6.8
6
4.0
2.1
4.8
3.3
7
8
4.0
4.8
3.3
2.1
9
0.4
1.6
1.0
1.4
0.4
10
1.4
1.6
1.0
11
1.3
0.2
1.1
12
1.3
0.2
1.1

Note: Balded values represent the mean hourly percent of drug released
as samples were drawn at two hour intervals
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Figure 1

Comparison of Dissolution Profiles: Metoprolol
Fumarate Osmotic Tablets (190 mg) with and without
HEC/R5'P coating
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Figure 2

Comparison of Dissolution Profiles: Metoprolol
Fumarate Osmotic Tablets (190 mg) coated with
HEC/RSP with and without 0.6 mm hole
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Figure 3

Comparison of Dissolution Profiles: HEC/R5P coated
Metoprolol Fumarate Osmotic Tablets (190 mg) in water
and 0.1 N HCI
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Figure 4

Comparison of Dissolution Profiles:
Dextromethorphan HBr Tablets (20 mg) with and
without HEC/R5P coating in Water
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Figure 5

Comparison of Dissolution Profiles:
Dextromethorphan HBr Tablets (20 mg) coated with
HEC/RSP with and without 0.25 mm hole
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Figure 6

Comparison of Dissolution Profiles: HEC/R5P
coated Dextromethorphan HBr Tablets (20 mg) in
water and 0.1 N HCI
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Figure 7
Scanning Electron Micrographs of Crosslinked HEC/RSP Coated Metoprolol
Fumarate Tablets before (7a) and after (7b) Dissolution Testing
Magnification 16.5 X
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7b
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Figure S
Scanning Electron Micrographs of Crosslinked HEC/RSP Coated Metoprolol
Fumarate Tablets before (Sa) and after (Sb) Dissolution Testing
Magnification 75 X
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PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES AS
SUSTAINED RELEASE COATINGS: PROBLEMS ASSOCIATED WITH AND
POSSIBLE SOLUTIONS FOR THE CHARACTERIZATION OF CROSSLINKED
MATERIALS
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PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES AS
SUSTAINED RELEASE COATINGS: PROBLEMS ASSOCIATED WITH AND
POSSIBLE SOLUTIONS FOR THE CHARACTERIZATION OF CROSSLINKED
MATERIALS

ABSTRACT
A method by which films of water soluble hydroxyethylcellulose may be
rendered insoluble, after deposition onto the surface of pharmaceutical solids,
has been developed. While the application of such a technology is rather simple
and offers promise as a substitute for organic solvent usage, the development of
meaningful analytical methodology, by which the crosslinking process may be
monitored and understood has proven rather difficult. Attempts have been made
to understand and quantify changes occurring to the polymer as a result of the
crosslinking reaction. Unfortunately many have proven inconclusive. Much of
the complexity of this problem lies in the insolubility of the crosslinked polymer in
common aqueous and organic solvents. Therefore considerable attention has
been paid to analytical techniques which may be performed on materials in their
solid state. The functional relevance of such techniques, as well as others
included in our previous work to large scale production is considered herein.
Additionally included is discussion of alternative techniques which, although not
tested with this system, may provided useful information about the crosslinking
process and provided recommendations for other ways to evaluate the
crosslinked product should instrumental methods fall short of their intended
goals.
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INTRODUCTION
In previous papers we describe a process by which hydroxyethylcellulose
(HEC}, a water soluble, nonionic polymer may be rendered water insoluble
through exposure to visible light when in the presence of riboflavin-5'-phosphate
(1 ). While the insolubilization of HEC has been demonstrated previously, we
believe our method is unique in that insoluble HEC may be obtained through
reaction with a photosensitizer that is currently approved for use in vivo (2-4).
The development of a system containing only GRAS components which may be
cured with visible light is notable in that previous attempts at radiation cured
coatings for pharmaceutical solids have suffered the shortcomings of
unapproved raw materials and the untoward effects of ionizing radiation (5,6).
In addition to the development of the HEC crosslinking process, (which may
circumvent the problems associated with unapproved materials) we have
demonstrated the potential of photocrosslinked HEC as a sustained release
tablet coating in vitro (7).
While we are confident that it is possible to alter the aqueous solubility of
HEC films applied to tablets and prolong the release of the drugs contained
within those films , our experience with this process has left us with many
unanswered questions. Simply put, there are aspects of this system that would
be difficult to characterize, let alone gain an understanding of the nature of the
chemical changes that have taken place. Fortunately, a complete
understanding of this system is not a prerequisite to its successful application.
Still, there exists a need for some reliable indicator of the extent of the
crosslinking process (quality control).
Generally, polymeric materials, especially those derived from natural
sources, are difficult to characterize. HEC is no exception having no conjugated
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bonds, thereby ruling out ultraviolet spectroscopy, very poor organosolubility
and poor water solubility, once crosslinked (1,8).
Official methods, both compendial (USP/NF) and ASTM , have been
developed for the identification of, and to set raw material acceptance criteria
specifications for, HEC (8,9). Unfortunately, these tests do not provide any
information about the chemical changes that may have taken place as a result
of the crosslinking reaction . Another official ASTM method which determines
the ethoxyl substitution of cellulose ethers may provide useful information about
the polymer if its level of ethoxyl substitution changes as a result of crosslinking
(10). Unfortunately, the utility of this method remains questionable since the
chemical changes that may be caused by crosslinking have yet to be
determined .
This paper seeks to gain insight into the nature of the crosslinking of
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HEC through common instrumental methods that could be used routinely in a
quality control setting. The methods included within this work were chosen in
the hope that they could elucidate any physico-chemical differences between
crosslinked and control samples of HEC without the need for complex testing
regimens . While this work has been concentrated on the characterization of
free films, it is hoped that the methods employed here for films may be readily
adaptable to coated tablets.

MATERIALS AND METHODS
Materials
Natrosol 250 M pharmaceutical grade hydroxyethylcellulose, molecular
weight 720,000 was supplied by The Aqualon Corporation (Wilmington, DE)
while riboflavin-5'-phosphate sodium was purchased from Sigma Chemical
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Corp . (St. Louis, MO ). All materials were used, as received from their
respective manufacturers without further purification.
Film Preparation
All films evaluated in this study were prepared in the following manner.
Formulation:
1.50 % w/w
0.03
98.47
100.00

Natrosol 250 M Pharma
Riboflavin-5'-phosphate
Water USP

The Natrosol and riboflavin-5'-phosphate were weighed and slowly
added to the vortex of a propeller type mixer (Lightnin' Labmaster TSR 1516)
operating at 1000 rpm . Any undissolved polymer, which remained after several
minutes of mixing was dispersed with the aid of a "lab scale" homogenizer
(Silverson L4R, UK) run at a slow speed so to lessen the possibility of reducing
the molecular weight of the polymer. Once free of any undissolved polymer, the
solution was transferred to a darkened refrigerator and allowed to deaerate
overnight. Prior to fi lm casting, the polymer solution was allowed to warm to
room temperature.
Once at room temperature, a suitable portion of the solution was poured
onto a preheated glass plate (60°C) and spread into a th in film (1.016 mm , wet
thickness) with the aid of a film casting table (RK Print - Coat Instruments, UK)
equipped with a # 8 cast ing rod . Once cast, the films were placed into a
darkened 6o 0 c oven and dried for 24 hours.
Those fi lms used for oxygen permeability testing were placed into an
environmental cab inet (Forma Scientific) previously calibrated to deliver 1000
footcandles of visible light at 25°C . Films were exposed to visible light for a
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period of 4, 8, 16, 24, or 168 hours, removed from the cabinet, and
subsequently stored in darkness until required .
Films that were evaluated by DSC , TGA, and IR spectroscopy were
subjected to either 600 footcandles of visible light for a period of 24 hours
(Hotpack environmental cabinet, model 352642, 25°C) or evaluated without
prior light exposure.

OXYGEN TRANSMISSIBILITY (Dk)
A Dk1000 Oxygen Permeability Apparatus (JDF Company, Norcross,
GA) was used for all oxygen transmissibility determinations. Testing was
performed in accordance with ASTM method 3985 (11)
Prior to testing each film sample was immersed in ultra pure water until
fully hydrated. Once hydrated, the films were cut into 1.5 x 1.5 cm squares, and
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reimmersed in water until needed for testing. The thickness of each individual
square was measured prior to its placement into the diffusion cell (0.35 cm2
exposed area).
The test cell of the Dk 1000 was then filled with ultra pure water, sealed
and subsequently purged with an inert carrier gas (2% H2 and 98% N2) until a
stable baseline was attained. Once stable, a humidified gas mixture containing
oxygen and nitrogen (79 and 21 % , respectively) was introduced into the cell.
Gradually, if the film is permeable, oxygen will diffuse through it and be carried
to the detector by the carrier gas. At the detector, an electrical current is
generated and converted to a signal that is directly proportional to the oxygen
flux through the film (12).
Wherever possible, Dk measurements were performed in triplicate.
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IR SPECTROSCOPY
Infrared spectra of HEC, R5P, and films representative of the different
stages of the crosslinking process were obtained with the aid of a Nicolet
Magna 550 FT-IR (Nicolet Instrument Corp. Madison, WI) operated under
normal conditions. Film samples were run , as received without any further
preparation while powder samples were finely ground, mixed with KBr and
compressed into pellets (40 ft.fib . compression force) . Prior to testing, excess
water and C02 were purged from the sample chamber with nitrogen. After
purging, each sample was scanned 100 times and its spectra plotted as percent
transmittance vs. frequency (4000 - 600 cm-1 ). Background spectra were
gathered each day prior to sample assay.

DSC, TGA

)

Differential scanning calorimetry (DSC) and thermogravimetric analyses
(TGA) were performed on samples of HEC which had been subjected to
different amounts of preparation. Films samples, prepared in a manner
consistent with those mentioned previously, were tested both before and after 6
days of exposure to 600 watts of visible light and compared to profiles obtained
for HEC powder tested "as received".
Calorimetry was performed, in duplicate under nitrogen, with the aid of a
Perkin Elmer DSC-7 (Perkin Elmer, Norwalk, CT). Samples were heated at a
rate of 10 CC/min over a temperature range of-60 to 125 oc.
TGA analyses of HEC samples similar to those evaluated by DSC were
performed with a Mettler TA 2000 C Thermogravimetric Analyzer (Mettler
Instruments, Switzerland) under both air and nitrogen. In each case heating
was maintained at a rate of 4 OC/min over a range of 25 to 600 degrees.
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RESULTS AND DISCUSSION
Oxygen Transmissibility
The oxygen transmissibility (Dk) of hydrogels is largely dependent upon
two factors, the material itself and the amount of water which it contains. While
the materials which make up a hydrogel (water excluded) may add a small
contribution to its overall Dk, its water content appears to have the greatest
influence on its Dk (12, 13). HEC will readily form hydrogels, a characteristic
which has been exploited for the creation of sustained release matrices (14) .
Matrices of this type gradually swell, once hydrated, and continue to do so until
all of the polymer has dissolved. Much the same can be said for uncrosslinked
films of HEC/R5P.
However once crosslinked, HEC/R5P films become insoluble, the degree
of which is dependent on the amount of crosslinking which has occurred.
Therefore, based on the statements of the previous paragraph, the Dk of
HEC/R5P films should decrease as their degree of crosslinking increases. This
was indeed the case in this study.
Table 2 displays the effect of different durations of visible light exposure
on the oxygen permeability of HEC/R5P films. From previous solubility studies
of crosslinked HEC/R5P films we have learned that the majority of the
crosslinking which will occur does so within the first 24 hours of exposure,
although additional exposure beyond 24 hours allows for additional crosslinking.
Samples that were exposed for 4 and 8 hour periods, although largely insoluble
in water, were difficult to handle due to their overall weakness when hydrated.
Because of these difficulties only two tests could be completed for those films
exposed for 4 hours.
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Statistical analysis of the oxygen permeability (Table 3) revealed
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significant differences between the mean Dk's of the 168 hour exposed films
and the remainder of the group except the 8 hour films whose mean had proved
to be marginally insignificant at an a of 0.05. The outcomes of the t-tests,
although they must be viewed caut iously because of small sample sizes,
confirm our observations. The extent of crosslinking of the 4 and 8 hour
samples is much more variable than that of films exposed for longer periods of
time.
Inconsistent crossl inking would allow portions of the HEC film to behave in a
manner more consistent with that of an uncrosslinked film . Areas of low
crosslink density would readily absorb large volumes of water and swell
considerably thereby forming a loose polymeric network which would readily
allow for the passage of oxygen and other, larger molecules. Conversely, those
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films with relatively high crosslink densities although hydrophilic, resist swelling
and maintain much of their mechanical strength when hydrated.

IR Spectroscopy
Spectra representing various combinations of HEC, R5P and visible light
exposure are presented in figure 1. A listing of the spectra presented in figure 1
may be found in table 1. Spectra of neat samples of HEC and R5P have been
included as controls by wh ich the spectra of crosslinked films may be judged.
Examination of figures 1b through 1f reveals no distinct differences
between the various cond itions of exposure below 1500 and above 2500
wavenumbers. Much of the difference in spectra between 2500 and 1500
wavenumbers may in fact be due to physical differences in the film samples and
not any distinct chemical change. Of course the addition of R5P to an HEC film
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causes a change in the appearance of the spectrum . Yet the presence, or
absence of peaks which correspond to those used for the identification of R5P
(1728, 1648, 1623 and 1578 cm-1) gives some insightto the role which R5P
has in the changes in HEC solubility encountered upon its exposure to visible
light (15).
Within figures 1d and 1f the benchmark peaks for R5P are clearly
evident, however they are no longer visible once the crosslinked film has been
washed with an excess amount of water (Figure 1f). The absence of R5P in
figure 1f is most encouraging as it leads to the assumption that R5P , or its
remnants have acted as true catalysts or photosensitizers, facilitating a
chemical reaction while remaining as separate moieties which may be readily
removed after accomplishing their intended task. Although a mechanism for
this reaction has not been determined, Holmstrom has suggested that riboflavin
is reduced upon exposure to light of sufficient energy (16). While the
mechanism proposed is beyond the scope of this discussion, it would be safe to
postulate that the reduced riboflavin has extracted a proton form the most
readily accessible source, in this case the HEC molecules which constitute the
majority of the film .
The ease by which R5P may be extracted from visible light exposed HEC
films , in conjunction with the notable differences in the aqueous solubilities of
visible light exposed films with and without R5P (1) leads to the assumption that
a crosslinking reaction has occurred, facilitated by the presence of a
photosensitizer. However the lack of significant changes in the infrared spectra
of the crosslinked films leads us to believe that the crosslinks achieved are few,
yet numerous enough to have a drastic effect on the polymer solubility.
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DSC , TGA
Thermograms of the three HEC samples evaluated are presented in
figure 2. Little, if any change in the thermal properties of HEC and the
HEC/RSP mixtures is evident, especially when one takes note that the heat
flows expressed on the y axis are less than 1mW overall. Therefore, any
apparent differences between the respective samples is exaggerated by the
scale on which they are presented.
The outcomes of TGA experiments, performed in air and nitrogen, are
presented in figures 3 and 4 respectively . Detectable mass loss commences at
about 21 o0 c for samples tested in air and about 22s 0 c for samples tested
under nitrogen. Both of these values are consistent with the 205 to 210 degree
"browning range" provided in the manufacturers technical literature (14).
Unfortunately, differences between polymer samples apparent in the TGA plots
are small and do not allow for the meaningful interpretation of the changes
imparted to the HEC as a result of the crosslinking reaction .

CONCLUSIONS
Although a process by which HEC may be crosslinked through visible
light exposure has been realized , a determination of what changes, if any, may
have occurred to the polymer has proven to be most difficult. While a detailed
mechanistic determination of the reaction between HEC, RSP and visible light
may be beyond the intended goals of this research , there exists a need for
analytical techniques by which the success and efficiency of this technique may
be monitored. Of the three analytical techniques discussed in this work, none
has provided direct proof of significant chemical changes to the polymer as a
result of crosslinking. Yet each of them , in some way , has provided insight into

102

)

the those changes which have taken place. Much of the data gathered, while
not conclusive of drastic changes imparted by light exposure, is nonetheless
suggestive of the nature of the few changes which must have occurred to effect
the alterations in solubility observed and are therefore, invaluable. The real
value of three of the methods which we had investigated lay in the
"circumstantial", and not the direct evidence which were gathered from them .
IR spectroscopy has revealed that no gross changes in the chemical
structure of HEC were effected as a result of the crosslinking reaction. Yet, our
attempt to "wash out" the R5P from the crosslinked films revealed that it may
indeed function as a true catalyst for crosslinking , acting only to facilitate
changes in the polymer without becoming chemically bound to it. Similarly,
DSC and TGA investigations demonstrated the similarities, and not differences
between the crosslinked and control HEC films.
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Circumstantial evidence has led us to postulate that water insoluble HEC
films are comprised of a weakly crosslinked polymeric network to which
chemical changes have been effected that are great enough in number to
impart drastic changes in aqueous solubility, yet few enough to not cause
significant changes in the polymer's thermal and infrared characteristics. This
effect may be largely due to the far greater contribution of polymeric inter-chain
interactions to the mechanical and thermal properties of HEC films , when tested
in a dry state, than those of the actual crosslinks created through visible light
exposure ( 17).
Unlike the circumstantial data proved by IR spectroscopy and thermal
analyses, oxygen transmissibility testing yielded data which provided a
quantitative, although quite preliminary, difference between films which had
been manufactured via different amounts of light exposure. The positive initial
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result of oxygen permeability testing has demonstrated it's potential value as a
test method to characterize crosslinked systems and provided hope that future
research may correlate, quantitatively, amount of crosslinking incurred as a
result of the dose of light applied. The success of this method is due to the fact
that measurements are performed on hydrated films . Hydration causes HEC to
swell considerably. Like other hydrogels, prolonged exposure of uncrosslinked
HEC to excess water leads to it's eventual salvation. Crosslinking locks
polymer molecules into fixed structures whose degree of swelling is determined
by the crosslink density. Therefore, the more crosslinked a polymeric film , the
less it can swell thereby resulting in a lower overall permeability.
While we have demonstrated the potential use of oxygen transmissibility
testing to differentiate between films of differing crosslink densities, the utility of
this technique for crosslinked tablet coatings remains questionable as it requires
the use of "free" films. Additionally , time might pose another hurdle since at
least 2 hours are required to run one sample.
Although the data gathered from oxygen transmissibility exhibits
quantitative differences between film samples subjected to different test
conditions, this test may not prove readily adaptable to an often performed
quality control procedure as would be required for the manufacture of
crosslinked tablet coatings. Likewise, the circumstantial evidence derived from
IR spectroscopy and thermal methods is rarely the basis for a system of quality
control. Clearly there exists a need for alternative test procedures capable of
distinguishing the changes that may occur within a photocrosslinkable coating
system while remaining efficient in both time and cost.
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At present, the only test which we have found to be both indicative of
crosslinking and feasible in respect to its use a quality control regimen is the
rather subjective determ ination of a film's aqueous solubility. This type of
testing is similar to the "acid bath" tests routinely employed for the evaluation of
the efficiency of enteric coatings. In the case of crosslinked HEC films , finished
tablets would be immersed in water and judged by the number of tablets whose
of coatings fail within a specified time period. Failure of a particular lot of tablets
would serve to indicate insufficient crosslinking and the subsequent need for
additional processing.
Although a solubility test similar to the one previously discussed is a
reasonable idea, in its' present form it is at best qualitative, and may not be
capable of discerning the subtle differences in the amount of crosslinking
incurred by a batch of tablets which may lead to failure of the coating in vivo.
Surely there are other techniques which, although as of yet untested, may
assist in the characterization of crosslinked HEC and other polymeric materials.
In the search for such tests one must remember that some test procedures may
provide information which may assist in the physico-chemical characterization
of a polymer, yet have no functional relevance to the performance of a
crosslinked system containing that polymer. Tests of this type are most useful
to the theoretical scientist wishes to understand the underlying mechanism by
which such a crosslinking reaction to occurs. The applied scientist's needs are
more simple. What he, or she, requires is a battery of test methods which are
indicative of if, and not necessarily descriptive of the manner in which a suitable
amount of crosslinking has occurred.
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Ideally the tests needed to monitor the processing of the type of
crosslinked coatings explored herein would be those which require minimal
sample preparation while allowing for the timely testing of many samples.
Unfortunately such methods may be unattainable. While the search for suitable
process monitoring assays continues, other actions may be taken to
characterize the crosslinking process so that reasonable process "end points"
may be determined. Future studies of photocrosslinked HEC coatings require
that investigators seek empirical tests which are clearly indicative off the extent
to which the reaction has occurred. If a simple testing regimen is not readily
forthcoming , validation of the irradiation process in conjunction with the
determination of meaningful process limits may offer a suitable means of
controlling the outcome of the crosslinking process.
The in situ crosslinked tablet coating technology which we have
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investigated in this, and previous papers, offers promise as a new means of
creating sustained release pharmaceuticals, yet the technology remains in its'
infancy. Future investigations need to find meaningful analytical techniques for
the crosslinked HEC and attempt to define the limits of the irradiation process.
If these needs are met, and regulatory agencies agree with the assumption that
a coating made from GRAS materials is itself a GRAS material, pharmaceutical
formulators may soon have a new sustained release technology at their
disposal.
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Table 1

Combinations of hydroxyethylcellulose and riboflavin-5'-phosphate studied by
infrared spectroscopy and presented in Figure 1

Figure
1a
1b
1c
1d
1e
1f

Com11osition
Ph~sical State
Riboflavin-5'-phosphate
KBr Pellet
Hydroxyethylcellulose 250 M
Film
Hydroxyethylcellulose 250 M
Film
HEC 250 M and 2 % R5P
Film
HEC 250 M and 2 % R5P
Film
HEC 250 M and 2 % R5P
Film
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Visible Light Ex11osure
None
None
7 days @ 600 ft. cand.
7 days @ 600 ft. cand.
7 days @ 600 ft. cand.
(H20 washed)? days@
600 ft. cand.

Figure 1 a

Infrared Spectrum of Riboflavin-5'-phosphate (Obtained from KBr Pellet)
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Figure 1 b
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Infrared Spectrum of Hydroxyethylcellulose (Natrosol 250 M) Free Film
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Figure 1 c

Infrared Spectrum of Hydroxyethylcellulose (Natrosol 250 M) Exposed to Visible
Light (600 footcandles) for 7 Days, Free Film
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Figure 1 d

Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin5'-phosphate (2% w/w) , No Light Exposure
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Figure 1 e

)

Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin5'-phosphate (2% w/w) , Exposed to Visible Light (600 footcandles) for 7 Days
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Figure 1 f

Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin5'-phosphate (2% w/w), Exposed to Visible Light (600 footcandles) for 7 Days
and Subsequently Washed with Distilled Water
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Figure 2

Thermograms of Selected Hydroxyethylcellulose Samples: Reference : Hydroxyethylcellulose 250
M Powder, Film Sample 1: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate
following exposure to Visible Light (600 footcandles , 6 days} , Film Sample 2: Film containing HEC
250 M and 2 % w/w Riboflavin 5' Phosphate , No light exposure . Note: Samples were heated
from -60 to 125 degrees centigrade (run 1), cooled and subsequently reheated (run 2).
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Figure 3
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Thermogravimetric analysis of various Hydroxyethylcellulose s~mples tested in air; Reference:
Hydroxyethylcellulose 250 M Powder (solid line), Film Sample 1: HEC 250 M and 2 % wlw
Riboflavin 5' Phosphate following exposure to 600 footcandles of Visible Light for 6 days (dashed
line) Sample 2: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate , No light
exposure {dotted line).
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Figure 4
Thermogravimetric analysis of various Hydroxyethylcellulose samples tested under nitrogen;
Reference: Hydroxyethylcellulose 250 M Powder (solid line), Film Sample 1: HEC 250 M and 2 %
w/w Riboflavin 5' Phosphate following exposure to 600 footcandles of Visible Light for 6 days
(dashed line) Sample 2: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate , No
light exposure (dotted line).

"
IO

Rckrcncc: N;1trosot I HCC
F'llm S:vnplc I 16 d Uchl uposurcJ
F'ihu S:unrilc l [no 11 Cht c.c1X1s.,rcl

lO

E.cpcri111cntal:
Mf:ITt,.Cn T ... 2000 C
.a1mo11.1h••~

hcauni:

~ :"~'::::

,.t~

tcmpuai.ucran,cr

)

·4 U '"""'"'

: 2S · GOO"C

"

:.:.:--

··-·~- ...

"
100

JOO

)
119

Tcmpcr.uurc

!"Cl

TABLE 2

The Effect of Visible Light Exposure on the Oxygen Permeability (Dk) of
Hydroxyethylcellulose Films

Exposure time
Trial 1
Trial 2
Trial 3
Mean Dk
Standard Deviation

4 hours
8.20E-10
1.06E-09

9.40E-10
1.70E-10

8 hours
9.BOE-10
1.48E-09
8.40E-10
1.10E-09
3.37E-10

16 hours
7.90E-10
7.60E-10
6.BOE-10
7.43E-10
5.69E-11

24 hours
6.70E-10
7.BOE-10
7.BOE-10
7.43E-10
6.35E-11

Note: Dk expressed in cc 02/cm2/sec/mm Hg
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168 hours
5.90E-10
5.60E-10
6.10E-10
5.87E-10
2.52E-11

TABLE 3

Statistical Analysis Comparing the Effect of Visible Light Exposure Duration on
the Oxygen Permeability (Dk) of Hydroxyethylcellulose Films

Results of Two Tailed T-Tests

8 hours

4 hours

16 hours

8 hours

0.601

16 hours

1.987

1.810

24 hours

1.943

1.804

0

168 hours

3.866T

2.635

4.363T

24 hours

3.972T

T Denotes significant difference at a = 0.05.

Note: For comparisons vs. 4 hours, where n=2, total degrees of freedom = 3.
In all other cases , degrees of freedom = 4. Critical t values for d.f. = 3
and 4 were 3.18245 and 2.7765, respectively at a = 0.05 for a two-tailed
t-test assuming equal variances.
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GENERAL CONCLUSIONS
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Within the modern pharmaceutical industry there is a need for new
coating materials which can prolong the release of medicaments from
their respective dosage forms. However, due to regulatory constraints
the chance of a new coating not composed of materials which are
"generally regarded as safe," ever entering the marketplace is rather
small.

•

Hydroxyethylcellulose (HEC) , a readily water soluble polymer, may be
rendered water insoluble through exposure to light, visible or ultraviolet,
when in the presence of riboflavin 5' phosphate.

•

Visible light exposure of Hydroxyethylcellulose films containing riboflavin
5' phosphate provides for superior yeilds of insoluble polymer than does

)

irradiation with ultraviolet light under the test conditions studied.

•

Once crosslinked, HEC is practically insoluble in water, acidic and basic
media (0.1 N), acetone, methanol, and aqueous urea. As urea is a
known decoupler of hydrogen bonds, hydrogen bonding is believed not
to be a significant cause of the polymer's change in solubility.

•

The idea of an in situ crosslinkable tablet coating for the sustained
release of mediaction has been realized . Such a coating may be applied
with extant technologies and be rendered insoluble via exposure to
visible light.

•

The ability of crosslinked HEC membranes to prolong and control the
release of both metoprolol fumarate and dextromethorphan HBr has

)
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been demonstrated in vitro. The mechanism of release does not appear

)

to be that of a semipermeable mebrane but rather membrane mediated
diffusion.
•

Although the crosslinking of HEC has been facilitated , analysis of the
crosslinked product has proven to be most difficult. Aside from relatively
qualitative solubility and swelling tests which can demostrate the
differences between samples which had been subject to different test
conditions , more quantitative techniques have proven elusive.

•

Data gathered from infrared spectroscopy, differential scanning
calorimetry, and thermo gravimetric analysis has proven to be largely
circumstantial in nature. While no direct changes to the polymer are

)

observed, their lack leads to the assumption that what changes have
occurred are too small in number to be detected by these methods, yet
numerous enough to drastically alter the solubility of HEC.
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SECTION Ill

)

•

Appendices 1, 2, and 3.

•

Complete listing of references cited.

)
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APPENDICES

1.
2.
3.

ASSAY VALIDATION : METOPROLOL FUMARATE
ASSAY VALIDATION : DEXTROMETHORPHAN HBr
UNITED STATES PATENT APPLICATION: "RADIATION CURED
DRU G RELEASE CONTROLLING MEMBRANE"

)
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Appendix 1

Assay validation report for metoprolol fumarate samples
in water and in 0.1 N HCI
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Appendix 1

Assay validation report for metoprolol fumarate samples
in water and in 0.1 N HCI
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ASSAY VALIDATION :
METOPROLOL FUMARATE TABLETS COATED WITH PHOTOCROSSLINKED
HYDROXYETHYLCELLULOSE

1. SOURCE of STANDARD :
Metoprolol fumarate, Lot# S-2-92-24, was prepared by the Chemical
Development Department, Ciba - Geigy Pharmaceuticals, Summit, NJ and
subsequently assayed and released for use as a reference standard by
the Physical and Analytical Chemistry Department, Ciba - Geigy
Pharmaceuticals, Suffern, NY ( attachment 1 ).
2. ASSAY:

Pump:
Injector:
Column Heater:
Column:
Detector:
Integrator:
Parameters:
Flow Rate:
Injection Volume:
Temperature:
Detector:

Shimadzu LC10AS
Waters WISP 712D
Eppendorf CH30
Shodex RS Pack D18-613 (15 cm)
Shimadzu SPD6AV, UVNIS
Waters 840 Chromatographic Data Station

1.0 ml/min.
30 µL
45oC
A. 272 nm, 0.02 AUFS

Solutions:
Ammonium Hydroxide (0.61 %)
Add 22 ml of ammonium hydroxide to approximately 500 ml distilled water
in a 1 liter volumetric flask, mix well , and dilute to volume with distilled
water.
Mobile Phase:
In a suitable flask combine 340 ml of acetonitrile, 660 ml of ammonium
hydroxide (0.61 %), and 34 ml of triethylamine. Mix well and degas under
vacuum for 1O minutes. Adjust pH to 11 .0 with acetic acid and filter through
a 0.5 µ Millipore filter, or equivalent, before use.
3. REPRESENTATIVE CHROMATOGRAMS:

)

The chromatograms presented in figures 1 through 9 represent the various
components present in the final , coated dosage form. They are as follows:
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Figure#
1

2
3
4

5
6
7
8
9

Description
Concentration (mg/mil
Water Blank
n/a
2.412x10-1
Metoprolol Fumarate in Water
Riboflavin 5' Phosphate in Water
4.038x10-"
Metoprolol Tablet (Uncoated) Water 2.11x10-1 (drug)
Metoprolol Tablet (Coated)
2.11x10-1 (drug)
HCI Blank
0.1 N
Metoprolol Fumarate in HCI
2.423x10-1
Riboflavin 5' Phosphate in HCI
4.038x10-4
Metoprolol Tablet (Uncoated) HCI
2.11x10-1 (drug)

The retention time of metoprolol fumarate was approximately 6.0 minutes
when assayed by this method.
4. LINEARITY:
The linearity of metoprolol fumarate in both distilled water and 0.1 N HCI
was determined by simple linear regression ("Cricket Graph" graphing
software, Computer Associates International, Inc. Islandia, NY). In each
case, seven separate concentrations of metoprolol fumarate were used to
generate the standard curve. Figure 10 depicts the standard curve, and
linear regression of metoprolol fumarate in water while figure 11 depicts
that of metoprolol fumarate in 0.1 N HCI.
The following concentrations were used for each linearity determination:
Solution#
1

2
3
4

5
6
7

Cone. in Water (mg/mil
2.412x10-1
2.171x10-1
1.447x10-1
9.648x10-2
4.824x10-2
1.929x10-2
4.824x10-3

Cone. in 0.1 N HCI (mg/mil
2.423x10-1
2.180x10-1
1.454x10-1
9.692x10-2
4.846x10-2
1.938x10-2
4.846x10-3

Suitable linearity was obtained in each case. Correllation coefficients for
linearity determinations in water and 0.1 N HCI were 9.995x10-1 and
9.997x1 0-1, respectively.
5. PRECISION :
Assay precision was determined by plotting the peak areas of triplicate
injections of metoprolol fumarate samples of known concentration against
the standard curves generated in the previous section. The mean %
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difference between the actual concentration of the samples and that
determined by the standard curve did not exceed 2.0% for any of the
individual concentrations/injections tested (see below). Plots of each
individual injection vs. their corresponding standard curve are presented in
figures 12 and 13.

Equation 1. Linearity of metoprolol fumarate in water:
Cone. metoprolol fumarate = 5.4435x1 Q-3 + 3.1563x10-1 x PEAK AREA

Sample#
1a
1b
1c
2a
2b
2c
3a
3b
3c

Cone. (actual)
(mg/ml)
1.998x10-1
1.998x10-1
1.998x10-1
9.999x10-2
9.999x10-2
9.999x10-2
4.995x10-2
4.995x10-2
4.995x10-2

Cone. (by Eq. 1)
(mg/ml)
2.034x10-1
1.999x10-1
2.045x10-1
1.004x10-1
1.005x10-1
1.005x10-1
5.017x10-2
5.068x10-2
5.178x10-2

% Difference
(cone.actual vs. by eg. 1)
1.80
0.05
2.35
0.41
0.58
0.58
0.44
1.46
3.67

(
Equation 2. Linearity of metoprolol fumarate in 0.1 N HCI:
Cone. metoprolol fumarate

= 3.8207x10-3 + 3.2073x10-7 x PEAK AREA

Sample#

Cone. (by Eq. 1)
(mg/ml)
2.057x10-1
2.083x10-1
2.077x10-1
1.006x10-1
1.016x10-1
1.025x10-1
5.048x10-2
4.997x10-2
5.003x10-2

1a
1b
1c
2a
2b
2c
3a
3b
3c

Cone. (actual)
(mg/ml)
2.039x10-1
2.039x10-1
2.039x10-1
1.019x10-1
1.019x10-1
1.019x10-1
5.099x10-2
5.099x10-2
5.099x10-2

% Difference
(cone.actual vs. byeg. 1)
0.85
2.13
1.83
1.35
0.37
0.51
1.00
2.00
1.88

6. SYSTEM SUITABILITY

(

System suitability tests were performed prior to each dissolution run
according to the specifications set forth in USP XXll. In each case, the
mean peak area and standard deviation of six replicate injections of a
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metoprolol fumarate standard solution were determined. Rejection was
made if the peak area standard deviation was found to be in excess of 2.0
percent.
Historical system suitability data is presented in attachment 2.

)
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Chromatogram of Riboflavin 5' Phosphate in Distilled Water
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Chromatogram of Metoprolol Fumarate Tablet (uncoated)
in Distilled Water

2S-Apr-94

42294

1.0 1 l.1.. 2 0

Printed on 25-Apr-•H at 13:t5154
Acquia1t1on •ethod

Quantitatton •ethod

loporoa

Unit a
Channel

I

Injec t loo
Run tiae

9 . 00

Injection volu•e

30

Acquialtlon veraion

6.21

I

Yi el

7
I
1.00 per sec

Total lnJectiona

I

• in
uL

loporos

syste• nu aber
Sa•ple rate
Mode

Calibration

Quant1tat1on version

6.21

UV/Yi:J

HPLC METHOD VALI DATION
HETOPROLOL FUNARATE IN RIBOFLAVIN SPOt COATED TABS

MET FUN CORE in H20

Chroaatogra• of 4.229t

..
30

25
20

10

_,
Peak ln e
UlllOVI

let t1H

Area

OIUOVI

2.f,3
2 . 92.

1995H
1362'

lopreuor

6. 12

64.0984

h1abt type
24097
1363
1172 6

135

Dn1at1on

Intercept

Slope

BB
IB
BB 6.t098ht05 5 . 6006••04

lespgnse

0.000••00

3 . 58S.t03

Figure 5
Chromatogram of Metoprolol Fumarate Tablet (coated)
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Figure 6
Chromatogram of 0.1 N HCI
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Figure 7
Chromatogram of Metoprolol Fumarate in 0.1 N HCI
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Chromatogram of Riboflavin 5' Phosphate 0.1 N HCI
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Figure 9
Chromatogram of Metoprolol Fumarate Tablet (uncoated)
in 0.1 N HCI
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Figure 10

Linearity: Metoprolol Fumarate in Water
y - 5 .4435E-3 + 3 .1563E-7x

r· 2 - 9 .9948E-1

3 . 000E - 1
Q)

"'
"'

2.SOOE- 1

E

:::>
LL.

..2

2 .000E-1

0

~~

c..-

2!:.

., ""

1. SOOE -1

~~
c:
0

-;;;

.,
=
<.>

c:

1. 000E- 1

S .OOOE-2

0

u
O. OOOE+O

. . . . . .

0

w
0
0

~

~

w

w

w

0
0

0
0

0
0

~

0

~

~

w

~

0

~

Peak Area

141

~

+
w

+
w

~

~

0

~

0
0

0
0

~

+
w

Figure 11

Linearity: Metoprolol Fumarate in 0.1 N HCI
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Precision: Metoprolol Fumarate Samples vs.
Standard Curve in Water
Note: Three Injections for each concentration
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Precision: Metoprolol Fumarate Samples vs.
Standard Curve in 0.1 N HCI
Note : Three Inj ections for each concentration
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Attachment 1

CIBA-GEIGY. CORPORATION

Physical and ~nalytlcal Chemistry
(Reference Standard)
METOPROLOL FUMARA.TE

1-Iaopropylamino-3-(p-( 2-methoxyethyl} phenoxyl J-2-propanol ( 2: l)
Fumarate Salt

Reference Standard No .:

Source:

(Reaaaay of S-2-87-20)

S-2-92-24

Chemical Development, . Summit

Sample Designation:

JI.mount availablet

CDF 2232 (Sample No . 83-695)
299 qrama

Kay 27, 1992
Reasaay Date:

May, 1997

Recommended Storage

Store in an amber glass bottle at room
temperature.

C~:mdition:

Dispense approximately S qrama per

Recommended Diepens inq Inatructione:

bottle.
Structure:

[~/""'"""""]

HOOC

H

\C•CI

I\

H

COOH

CH~20CH3

'
Molecular Weight:

1.

Description:

2.

Spectroscopy:

Empirical Formula:

650. 79

C,..Hs.tff~ 10

Clean, white crystalline powder.

Infrared Spectrum
The infrared spectrum, obtained as a nujol mull, is comparable to
the previous metoprolol fumarate reference standard S-2-87-20. The
following assignments are consistent with the structure of
metoprolol fumarate.
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Wavenumber

rem·•)

1612
1517
1244
1195
1113
1051
990
812
J.

Aaa ignmenta
Aromatic ring, carboxylate ion
ArOCDatic rin9
Aromatic ether
taopropyl qroup
Aliphatic ether, •econdary alcohol
1-4 Di•ub•tituted benzene
C•C

1-4 Diaub•tltuted benzene

Chromatographic Impurities - Liauid Chromatography/Thin Layer
Chromatoqraphyt
Thin-Layer Chromatography:
CHClJ (under Nils atmosphere], Silica Cal CF 254, 250 µm layer:
the 200 µ9 level. Total impurities detected leas than O.l\.
b.

At

Liquid Chrsxpatography:

LC \: 1.mpuritiea • O.l\: (by percent area normalization)
LC + TLC total impurities • 0.2\
Column:
·Mobile Pha•e:

Detection:
Sensitivity:
Flow Bate:
Temoerature:

µBondapak c 11 (Water• A••ociate•, 30 cm x 3.9 mm IO)
Acatonitrile/waur (380 mL/1620 mL) containinq 7. 8 qm
of umoniu.m aceta.te, 4. 0 mL of triethylam.ine, 20 mL
ot qlacial acetic acid, and 6.0 mL of phosphoric
acid.
Ultra.viOlet detector (275 nm}
0.01 AUFS
1 mL/minute

4oac

pry at 60•c under vacuum tor tour hour•:

4.

Losa on prying -

S.

aaaa.y - Nonaoueoua titration <HClO.l:

0.02'

99. S\ (dried baoio)

Thia material la auitable for use a.a a. reference atandard for Lopraaaor.
Reference: .

NB-132 RIC #67 /130

~.b.
RX:ap
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Attachment 2

SYSTEM SUITABILITY DATA

Metoprolol Fumarate Assay
Acceptance Criteria: rsd > 2.0%

Run Date
Mg Eq. Standard
Injection#

1
2
3
4
5
6
Mean Peak Area
Standard Dev.
Rsd%
Run Date
Mg Eq. Standard
Injection#

1
2
3
4
5
6
Mean Peak Area
Standard Dev.
Rsd%

11/3/93 11/12/9311/16/9311/17/94 5/4/94

5/6/94

188.64

194.81

194.81

188.17

180.81

180.81

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

633962 641233 696370 649744 617486 625682
628092 640588 708284 645780 619004 610162
629994 647129 713181 640102 616919 618400
627219 642045 707666 641716 619151 618656
623836 640102 727169 639494 623214 622584
627351 647397 721446 634094 622220 616304
628409.00 643082.33 712352.67 641821 .67 619665.67 618631 .33
3079.40 3016.40 9973.82 4941 .91 2313.48 4874.01
0.490
0.469
1.400
0.770
0.373
0.788
5/8/94

5/10/94 5/13/94 5/16/94 5/17/94 5/20/94

180.81

190.00

190.00

197.86

197.86

190.03

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

649420 664148 669201 694088 697328 670669
628946 661572 663634 693349 698670 690437
643949 654365 662022 685917 701430 673783
634409 661266 662251 696255 701116 661335
629780 660908 661826 692735 692355 665846
663134 656475 661153 689348 705019 656580
641606.33 659789.00 663347.83 691948.67 699319.67 669775.00
12123.87 3317.03 2721 .38 3387.35 3938.23 10836.36
1.890
0.503
0.410
0.490
0.563
1.618
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Appendix 2

Assay validation report for dextromethorphan HBr samples
in water and in 0.1 N HCI
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ASSAY VALIDATION:
DEXTROMETHORPHAN HBR TABLETS COATED WITH
PHOTOCROSSLINKED
HYDROXYETHYLCELLULOSE

1. SOURCE of STANDARD:
Dextromethorphan HBr, Lot# S-1-90-17, was prepared by the Chemical
Development Department, Ciba - Geigy Pharmaceuticals, Summit, NJ and
subsequently assayed and released for use as a reference standard by
the Physical and Analytical Chemistry Department, Ciba - Geigy
Pharmaceuticals, Suffern, NY ( attachment 1).
2. ASSAY:

Pump:
Injector:
Column:
Detector:
Integrator:
Parameters:
Flow Rate:
Injection Volume:
Temperature:
Detector:

Shimadzu LC10AS
Waters WISP 7120
Whatman Partisil 5 ODS - 3 (15 cm)
Shimadzu SPD6AV, UVNIS
Waters 840 Chromatographic Data Station

1.25 ml/min.
50 µL
Ambient
I.. 280 nm, 0.01 AUFS

Solutions:
Mobile Phase:
In a suitable flask combine 700 ml of acetonitrile, 300 ml of distilled water,
2.21 g docusate sodium and 400.3 mg ammonium nitrate. Mix well and
degas under vacuum for 10 minutes. Adjust pH to 3.05 with acetic acid and
filter through a 0.5 µMillipore filter, or equivalent, before use. Discard after
twenty four hours.
3. REPRESENTATIVE CHROMATOGRAMS:
The chromatograms presented in figures 1 through 9 represent the various
components present in the final , coated dosage form. They are as follows:
Figure # Description
1
Water Blank
2
Dextromethorphan HBr in Water
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Concentration (mg/mil
n/a
4.0x10-2

3
4

5
6
7

8
9

4.038x10-4
Riboflavin 5' Phosphate in Water
Dextromethorphan Tablet (Uncoated) Water 4.0x10-2 (drug)
4.0x10-2 (drug)
Dextromethorphan Tablet (Coated)
0.1 N
HCI Blank
4 .01x10-2
Dextromethorphan HBr in HCI
4.038x10-4
Riboflavin 5' Phosphate in HCI
4.0x10-2 (drug)
Dextromethorphan Tablet (Uncoated) HCI

The retention time of Dextromethorphan HBr was approximately 5.1
minutes when assayed by this method.
4. LINEARITY:
The linearity of Dextromethorphan HBr in both distilled water and 0.1 N HCI
was determined by simple linear regression ("Cricket Graph" graphing
software, Computer Associates International, Inc. Islandia, NY). In each
case, seven separate concentrations of Dextromethorphan HBr were used
to generate the standard curve . Figure 10 depicts the standard curve , and
linear regression of Dextromethorphan HBr in water while figure 11 depicts
that of Dextromethorphan HBr in 0.1 N HCI.
The following concentrations were used for each linearity determination:

)

Solution#

1

2
3
4
5
6
7

Cone. in Water (mg/mil
7.946x10-2
3.973x10-2
3.178x10-2
2.543x10-2
1.589x10-2
7.946x10-3
2.384x10-3

Cone. in 0.1 N HCI (mg/mil
8.012x10-2
4.006x10-2
3.205x10-2
2.564x10-2
1.602x10-2
8.012x10-3
2.404x10-3

Suitable linearity was obtained in each case . Correllation coefficients for
linearity determinations in water and 0.1 N HCI were 9.995x10-1 and
9.997x10-1, respectively.
5. PRECISION :
Assay precision was determined by plotting the peak areas of triplicate
injections of Dextromethorphan HBr samples of known concentration
against the standard curves generated in the previous section. The mean
% difference between the actual concentration of the samples and that
determined by the standard curve did not exceed 4.4% (mean %
differences: 2.11 for water and 1.62 for 0.1 N HCI) for any of the individual
concentrations/injections tested (see below). Plots of each individual
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injection vs. their corresponding standard curve are presented in figures 12
and 13.

Equation 1. Linearity of Dextromethorphan HBr in water:
Cone. Dextromethorphan HBr = 2.8207x1o-4 + 7.9307x10-8 x PEAK AREA

Sample#
1a
1b
1c
2a
2b
2c
3a
3b
3c

Cone. (actual)
(mg/ml)
2.861x10·2
2.861x10·2
2.861x10·2
1.907x10-2
1.907x10-2
1.907x10-2
4.768x10-3
4.768x10-3
4.768x10·3

Cone. (by Eq. 1)
(mg/ml)
2.935x10-2
2.987x10-2
2.955x10·2
1.951x10-2
1.954x10-2
1.928x10·2
4.787x10-3
4.837x10-3
4.721x10-3

% Difference
(cone.actual vs. bl£'. eg. 1 l
2.59
4.40
3.29
2.31
2.46
1.10
0.40
1.45
0.98

Equation 2. Linearity of Dextromethorphan HBr in 0.1 N HCI :

)

Cone. Dextromethorphan HBr = 2.0129x10-4 + 7.75535x10-8 x PEAK AREA

Sample#
1a
1b
1c
2a
2b
2c
3a
3b
3c

Cone. (actual)
(mg/ml)
2.884x10·2
2.884x10-2
2.884x10-2
1.923x10-2
1.923x10-2
1.923x10-2
3.205x10-3
3.205x10·3
3.205x10-3

Cone. (by Eq. 1)
(mg/ml)
2.927x10·2
2.960x10-2
2.957x10-2
1.957x10-2
1.951x10-2
1.935x10-2
3.186x1 Q-3
3.295x10-3
3.226x10-3

% Difference
(cone.actual vs. bl£'. eg. 1)
1.49
2.64
2.53
1.77
1.46
0.62
0.59
2.81
0.65

6. SYSTEM SUITABILITY
System suitability tests were performed prior to each dissolution run
according to the specifications set forth in USP XXll. In each case,the
mean peak area and standard deviation of six replicate injections of a
Dextromethorphan HBr standard solution were determined. Rejection was
made if the peak area standard deviation was found to be in excess of 2.0
percent.
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Historical system suitability data is presented in attachment 2.
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Figure 1
Chromatogram of Distilled Water
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Figure 2
Chromatogram of Dextromethorphan HBr in Distilled Water
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Figure 3
Chromatogram of Riboflavin 5' Phosphate in Distilled Water
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Figure 4
Chromatogram of Dextromethorphan HBr Tablet (uncoated)
in Distilled Water
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Figure 5
Chromatogram of Dextromethorphan HBr Tablet (coated)
in Distilled Water
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leaponse

Figure 6
Chromatogram of 0.1 N HCI
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Figure 7
Chromatogram of Dextromethorphan HBr in 0.1 N HCI
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Figure 8
Chromatogram of Riboflavin 5' Phosphate 0.1 N HCI
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Figure 9
Chromatogram of Dextromethorphan HBr Tablet (uncoated)
in 0.1 N HCI
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Figure ·10

Linearity : Dextromethorphan HBr in Water
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Linearity: Dextromethorphan HBr in 0.1 N HCI
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Figure 12

Precision: Dextrornethorphan HBr Samples vs.
Standard Curve in Water
Note : Three injections at each concentration
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Figure 13

Precision: Dextromethorphan HBr Samples
vs. Standard Curve in 0.1 N HCI
Note : Three injections at each concentration
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Attachment 1

CIBA-GEIGY CORPORATION
Physical and Analytical Chemis try
(Reference Standard)

Dextromethorphan Hydrobromide

Reference Standard No . :
Source:

Sample Designation:
Amount Available:
Date :

)

S-1-90-17

Batch No . NA-1-97
971 g

June 1, 1990

Reassay Date:

June, 1995

Recommended Storage Conditions:

Store in a tight, light-resistant
container

Structure :

Molecular Weight:

1.

(Reassay of S-1-85-21)

Chemical Development, Summit

370 . 33

Description:
White crystalline powder .
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2.

Infrared Spectroscopy:
The spectrum is consistent with the structure indicated.
Assignments

3283
2926,2857
1616
1576, 1498
1463
1281,1170
1244, 1071, 1042
86 7. 775. 727 '693
3.

Liquid Chromatography :

Column :
Mobile Phase :

)

Detector :
Flow Rate :
Sensitivity :
Temperature:
Assay:
4.

5.

C-H stretching
-CH 2 bending
H-0 stretching
C=C stretching, aromatic ring
-CH3 bending
C-N stretching, tertiary amine
-OCH 3 stretching
C-C out-of-plane bending, aromatic ring

µBondapak C18 (llaters) 30 cm x 3 . 9 Diil ID , or
equivalent
Dissolve 3.1 g of docusate sodium in 1000 mL of
acetonitrile/water (70 : 30), add 560 . 4 mg of
ammonium nitrate, adjust the pH to 3 . 4 with
acetic acid, mix and filter the solution through
a 0 . 45 µm Millipore FH filter (or equivalent) .
Degas the mobile phase before use.
UV - 280 nm
l mL/minute
0.1 AUFS
Ambient
99 . 6'1,,-anhydrous basis (external standard method)

Identification :

4. 1

Infrared Absorption :
Conforms to previous reference standard .

4.2

Ultraviolet Absorption :
Conforms to previous reference standard .
Absorptivity of sample vs . USP reference standard= 0 . 78'1.
(anhydrous basis)

4.3

Bromide:
Positive

pH (l in 100) :
5.5

6.

Water Content :

4 . 72'1.
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This sample is suitable for use a s a reference standard in testing
o f Dextromethorphan Hydro bromide .

Reference:

HB #94/52

ti. Bordun

HB:ap

)
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Attachment 2

SYSTEM SUITABILITY DATA

Dextromethorphan HBr Assay
Acceptance Criteria: rsd > 2.0%

Run Date
Mg Eq. Standard
Injection#

1
2
3
4
5
6

)

Mean Peak Area
Standard Dev.
Rsd%
Run Date
Mg Eq. Standard
Injection#

1
2
3
4
5
6
Mean Peak Area
Standard Dev.
Rsd%

5/26/94 5127194 5/31/94

20.67

20.67

20.88

6/1/94

20.68

6/2194

20.68

6nt94

19.86

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

Peak
area

537812
538292
538087
537131
533114
529696

535713
536078
530820
518856
521248
518993

541428
544172
540179
542329
539765
544293

529917
531170
533341
534753
536848
530106

541938
542156
539409
540720
539939
543389

438031
437841
437693
435689
435679
435608

535688.67 526951 .33 542027.67 532689.17 541258.50 436756.83

3205.70 7488.07 1766.24 2537.90 1369.79 1102.81
1.421
0.326
0.476
0.253
0.252
0.598
6/10/94 6/12194 6/14/94

19.86

19.57

Peak
area

Peak
area

519894
523396
524883
527527
519913
505843

519673
520254
516610
521182
522027
519322

19.57
Peak
area

513199
515779
516325
512937
516220
518435

520242.67 519844.67 515482.50

6977.56 1707.06 1904.07
0.328
0.369
1.341
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Appendix 3

United States Patent Application entitled: "Radiation Cured Drug Release
Controlling Membrane" and documents concerning its receipt by U.S. Patent
Office.

)
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CGC 1740
RADIATION CURED DRUG RELEASE CONTROLLING
MEMBRANE

Inventor:

Gary Van Savage, residing at 1O Flanders Way, Bridgewater, New
Jersey 08807, a citizen of the United States of America; and
James Merl Clevenger, residing at 432 Little Brook Road, Glen

)

Gardner, New Jersey 08826, a citizen of the United States of
America.

Prepared by:

Karen G. Kaiser, Esq.
Patent Department
Ciba - Geigy Corp.
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Background of the Invention

This invention relates to cross-linked hydrophilic polymeric films, the process of
making such films, and their use in applications where strength of the polymer
article and high permeability to water are required simultaneously. In particular,
these films are suitable for use as a carrier for biologically active agents, such as
pharmaceuticals, both human and veterinary, insecticides, and fertilizers; as
hydrophilic membranes for separation processes; as bandages for wound
treatment; as body implants or as coatings for such implants; and as coatings on
glass, metal , wood or ceramics.

Such films, particularly when used as biological carriers, should not only be able

)

to entrap the biological agent, but should also be biocompatible; that is, both
mild and non-cytotoxic to living organisms. Additionally, they should be
chemically and mechanically stable.

Cross-linked polymeric films have been made. For example, U.S. Patent Nos.
2,976,576 and 3,220,960 disclose cross-linked hydrophilic polymers which are
produced by polymerizing a hydrophilic monomer in the presence of a crosslinking agent; U.S. Patent No. 3,520,94 discloses hydrophilic cross-linked
polymers which are produced by admixing a water-soluble polymerizable
hydroxyalkyl monoester of a mono-olefinic monocarboxylic acid and a
polymerizable diester of a mono-olefinic monocarboxylic acid in the presence of
a linear polyamide; and U.S. Patent Nos. 4,192,827 and 4,277,582 disclose
cross-linked polymers which are produced from a polymer of mono-olefinic
monomers or copolymers of mono-olefinic monomers which is cross-linked with
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a terminal diolefinic hydrophobic macromer. However, the use of monomers is
disadvantageous in the pharmaceutical industry due to the potential cytotoxicity
of unreacted monomers.

Other cross-linked polymeric films have been made from polymers, thereby
overcoming the problem of unreacted monomers. For example, WO 93/09176
discloses cross-linking of polysaccharides, polycations and lipids with
polymerizable acrylate in the presence of a radical initiator by using certain
sources of energy; U.S. Patent No. 3,077,468 discloses the method of crosslinking water-soluble hydroxyalkyl polysaccharide ethers by reacting them with
an insolubilizing agent selected from unsaturated dibasic aliphatic acids and
their anhydrides and the water-soluble derivatives of said acids and their
anhydrides; and U.S. Patent No. 3,272,640 discloses cross-linking water-

)

soluble polymers by reacting them with a hydrophobic film former.

Summarv of the Invention

It is accordingly an object to the present invention to provide cross-linked,
hydrophilic polymeric films which are suitable for use as a carrier for biologically
active agents, such as pharmaceuticals, both human and veterinary,
insecticides, and fertilizers; as hydrophilic membranes for separation processes;
as bandages for wound treatment; as body implants or as coatings for such
implants; and as coatings on glass, metal, wood or ceramics.

It is another object of this invention to provide such a film which is essentially
insoluble in aqueous and non-aqueous solutions.
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It is yet another object of this invention to provide a cross-linked hydrophilic
polymeric film which can be prepared without the use of organic solvents.

It is still another object of this invention to provide a cross-linked hydrophilic
polymeric film which is safe for in vivo usage.

These, and other objects apparent to those skilled in the art from the following
detailed description, are accomplished by the present invention which pertains
to cross-linked hydrophilic polymeric films , the process of making such films, and
their use. These films are produced by the application of an aqueous solution of
a water-soluble polymer and a photosensitive or light degradable catalyst to a
suitable substrate, optionally drying said solution, and exposing the resultant film
to a suitably interacting energy source.

)
Detailed Description of the Invention

This invention pertains to cross-linked hydrophilic polymeric films , the process of
making such films, and their use. These films are produced by the application of
an aqueous solution of a water-soluble polymer and a photosensitive or light
degradable catalyst to a suitable substrate, optionally drying said solution, and
exposing the resultant film to a suitably interacting energy source.

Appropriate polymers are those which are water-soluble and possess a structure
which, in the presence of a suitable catalyst or cross-linking agent, may bond to
additional molecules, thus yielding a macromolecule of said polymer which, due
to its increased molecular weight, is no longer readily soluble in an aqueous
medium. These polymers include, but are not limited to, water-soluble polyvinyl
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alcohols, poly(hydroxyethyl methacrylates), and polysaccharides, particularly
hydroxyalkyl polysaccharide ethers, more particu larly cellulose ethers such as
hydroxyethyl cellulose and hydroxypropyl methylcellulose. Polymers which have
low viscosities are preferred; those which have viscosities which approach that
of water are most preferred.

The amount of polymer used is that which can be solubilized in water and still
remains free-flowing . A solution with a viscosity near that of water is preferred.
Particularly, from about 1.0 to about 30% (w/w), more particularly from about 1.0
to about 6.0% (w/w) of the polymer is used.

Appropriate catalysts include those which are photosensitive or light degradable,
such as azo dyes and riboflavin. The catalysts include, but are not limited to,

)

riboflavin and its derivatives, Congo red , Evans blue, chlorazodin, ery1hrosine
(FD&C Red #3), FD&C Red #40, tartrazine (FD&C Yellow #5), fast green FCF
(FD&C Green #3), sunset yellow FCF (FD&C Yellow #6), brilliant blue FCF
(FD&C Blue #1 ), and indigotine (FD&C Blue #2). In particular, the catalyst is a
flavin . More particularly, the catalyst is riboflavin or a riboflavin derivative,
preferably water soluble riboflavin derivatives, including, but not limited to,
riboflavin-5'-phosphate or a salt thereof, riboflavin-5'-adenosine diphosphate, 6hydroxyriboflavin, 8-nor-8-hydroxyriboflavin, roseoflavin , 5-deazariboflavin, 8a(N 1-histidyl)flavin, 8a-(N3-histidyl)flavin, 8a-S-cysteinylflavin, 6-S-cysteinylflavin,
lumiflavin, and lumichrome. Most particularly the catalyst is riboflavin-5'phosphate sodium.

Typically 0.1 to 10% (w/w), more particularly from about 1.0 to about 4% (w/w) of
the catalyst is used, based on the total weight of the solids (polymer plus
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catalyst) in solution. Before forming the film , the solution of polymer plus
catalyst may be deaerated so as to decrease the amount of air trapped within
the final product. Deaeration may be accomplished by allowing the solution to
stand, particularly in a darkened, refrigerated room , ie. overnight, or by
conventional methods known in the art. Although it is not necessary, deaeration
generally improves the quality of the resultant film .

To form the film , the polymer is applied to a substrate. If the film is to be formed
separately, as opposed to being coated onto an object, the substrate should be
a smooth, non-reactive surface, ie. glass. Application may be by any
conventional method known in the art.

The film is preferably allowed to dry before exposure to the energy source.

)

Although th is will occur at ambient temperatures, heat and or vacuum may be
applied to decrease drying time. The film is preferably allowed to dry to a water
content of no more than 30% , more narrowly to one of no more than 10%.
However, as the film is hydrophilic, it is common for it to pick up water, thus
rehydrating to some extent.

The energy source used to cure the polymer may be any type of electromagnetic
radiation, such as actinic light, x-rays, or gamma radiation . Light sources,
particu larly those within the ultraviolet or visible range , are preferred, particularly
those with wavelengths of from approxi mately 200 to approximately 800
nanometers, more particularly those with wavelengths of from approximately 300
to approximately 700 nanometers. When the polymer is to be used as a carrier
for a biologically active agent, particularly pharmaceuticals, it has been found
)

that light within the visible range is most preferred because of the potential for
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degradation of the active agent outside of this range. The wavelength most
suited to use in any particular curing will depend upon the catalyst chosen.

The film should be exposed to the energy source for such time as is necessary
to achieve the desired amount of cross-linking of the polymer, particularly for
such time as is necessary to ensure that the film is no longer freely soluble in an
aqueous medium. The exposure time is dependent upon the intensity and type
of energy source used as well as the type of polymer and thickness of the film.
Sufficient exposure is generally indicated by a change in film color due to the
catalyst. For example, the film turns from a bright yellow to a yellow-brown color
when riboflavin or a derivative thereof is used as the catalyst.

Surprisingly, the instant reaction will occur in the presence of oxygen unlike

)

many others in which free radical scavenging inhibits the reaction. In addition,
when the energy source used is light, the reaction is substantially temperature
independent within the range of 0-100°C though ambient conditions are
considered to be best. The reaction may proceed without organic solvents.
Whenever organic solvents are used in a pharmaceutical process, measures
need to be taken to protect the operators who produce the dosage forms and the
environment from overexposure to the hazardous, often teratogenic and
carcinogenic, materials. Additional precautions are necessary to protect
equipment and facilities from harm. Further, despite all precautions, it is still
likely for detectable levels of residual solvent to remain in the finished dosage
form . Not only is the instant process advantageously safer, but the resultant film
is safer in that it does not contain residual organic solvents. Thus, the present
reaction, which may proceed without organic solvents, is advantageous,

)

especially in the pharmaceutical industry.
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Another safety advantage in the pharmaceutical industry is that since polymeric,
not monomeric, materials are used, the cytotoxic potential of unreacted
monomers is eliminated. Further, the film may be made with ingredients which
are "generally regarded as safe" (GRAS) by the Food and Drug Admin istration.

The cured polymer may be applied using any conventional coating technique
including, but not limited to, spray coating, dip coating, and fluidized bed
coating. The resultant film is substantially water insoluble and hydrophilic.
Further, it tends to be insoluble in both acidic and alkaline solutions. The film is
not appreciably elastic, but is flexible and continuous.

The possible film thickness is dependent upon the light penetration. If thicker
films are desired, however, multiple layers may be applied successively, each
layer being cured before the next layer is deposited. This is especially useful in
coating processes, for example coating of a pharmaceutical dosage form .

The resultant film can be used, inter alia, as a carrier for biologically active
agents, particularly pharmaceutically active agents. The term "pharmaceutically
active agent," as used herein, refers to any composition of matter which will
produce a pharmacological or biological response , including pharmaceuticals
which are used to treat the body topically as well as systemically. Suitable
mixtures of such active agents can be dispensed with equal facility as with single
component systems. Furthermore, derivatives of these pharmaceutically active
agents, eg. ethers, esters, amides, etc. , which are easily hydrolyzed within the
body can be employed as can various forms of the active agents, eg. salts,
acids, complexes, etc.
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Pharmaceutically active agents useful in the present invention include, but are
not limited to, proteins and peptides, antiasthmatics, antianginals,
corticosteroids, 5-lipoxygenase inhibitors, antihypertensives, and leukotriene 84
receptor antagonists. Proteins and peptides include, but are not limited to,
transforming growth factors (TGF), immunoglobulin E (lgE) binding factors ,
interleukins, interferons (IFN), insulin-like growth factors (IGF), milk growth
factors , anticoagulants, anabolics, analgesics, androgens, antibiotics,
androgens, antidepressants, antidiabetics, anticonvulsants, antihistamines,
antihypertensives, antiinfectives, antiparasistics, antiparkinson agents,
antiphlogistics, antitussives, appetite depressants, bronchodilators, coronary
dilators, corticoids, cytostatics, diuretics, hypnotics, neuroleptics, psychoanaleptics, tranquilizers, uricosurics, vasodilators, and parathyroid hormones

)

(PTH). Specific active agents include, but are not limited to IGF-1, PTH (1-34)
and analogues thereof, TGF w TGF 131 • TGF l32•TGF l33• IF Na, hybrid IF Na, IFNy,
hirudin, heparin, calcitonin, 5-aminosalicylic acid, CGS 23885, CGS 25019C,
CGS 26529, Zileuton, ONO-LB 457, beclomethasone dipropionate,
betamethasone-17-valerate, prednisolone metasulfobenzoate, tixocortol
pivalate, budesonide, fluticasone, metoprolol fumarate , metoprolol tartrate,
tetrahydroaminoacridine (THA), galanthamine, theophylline, ursodiol,
clomipramine hydrochloride, terbutaline sulfate, aminoglutethimide,
deferoxamine mesylate, estradiol, isoniazid, metyrapone, methandrostenolone,
acetylsalicylic acid, phenylbutazone, methadone, methyltestosterone,
imipramine, maprotiline, phenformin, carbamazepine , tripelennamine,
hydralazine, trimethoprim, nifurtimox, levodopa, naproxen, benzonatate,
mazindol , fenoterol , fenalcomine , dexamethasone, floxuridine,
hydrochlorothizide, glutethimide, reserpine, methylphenidate, diazepam,
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sulfinpyrazone, isoproterenol, and rifampin .

As used herein, the active agents CGS 23885, 25019C, CGS 26529, Zileuton,
ONO-LB 457 are defined as follows: CGS 23885 refers to N-hydroxy-N-((6phenoxy-2H-1-benzopyran-3-yl)methyl)- urea; CGS 25019C refers to 4-[5-[4(aminoiminomethyl)phenoxy] pentoxy]-3-methoxy-N ,N-bis( 1methylethyl)benzamide (Z)-2-butenedioate; CGS 26529 refers to N-[2-[[2-[[4-{4fluorophenyl)phenyl]methyl]-1 ,2,3,4-tetrahydro- 1-oxo-6-isoquinolinyl]oxy]ethyl]N-hydroxyurea; Zileuton refers to 1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea;
ONO-LB 457 refers to 5-[2-(2-carboxyethyl)-3-{6-(para-methoxyphenyl)-5Ehexenyl} oxyphenoxy] valeric acid.

Incorporation of the biologically active agent into the polymeric film may be
accomplished by dissolution or dispersion into the polymer solution prior to
curing or by diffusion into the finished article after cross-linking has occurred. In
the alternative, the polymeric film can be hydrated in a solution of the active
agent to be delivered and the solvent is then evaporated, leaving the agent
within the film.

The biologically active agent may also be incorporated by techniques known in
the art, for example microcapsules could be formulated by air-jet droplet
generation, co-axial extrusion, or by emulsification. Incorporation may also be
accomplished by coating the agent, either alone or admixed with acceptable
excipients, using coating techniques known in the art, for example spray-coating
or fluidized bed coating.

A pharmaceutical dosage form, such as a tablet or capsule, may alternatively be
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coated by admixing the polymer and catalyst, compression coating said mixture
onto the pharmaceutical dosage form, and then exposing the compression
coated form to the energy source. In this manner, the film is formed without any
solvents. Techniques known in the art may be used to optimize this process; for
example, the polymer/catalyst mixture may be ground to an appropriate particle
size or acceptable tabletting agents may be added to the mixture.

The amount of the biologically active agent incorporated within the film may vary
widely depending upon the particular agent, the desired therapeutic effect, and
the time span of release.

As a carrier, the film may be used as a semi-permeable membrane for controlled
release delivery systems. The film may be used to coat products for controlled

)

sustained release of their contents as is or the coated product may be further
outfitted with an orifice for release of active agent. In this latter embodiment, the
coated product functions in a manner similar to those utilizing the oral osmotic
technology known under the Alza tradename OROS/. This product permits
passage of water and certain dissolved materials, but retains others, thus
allowing active agent to be emitted at a controlled rate . The films of this
invention however differ from the typical semipermeable membrane used in an
OROS-type system in that a release orifice is optional, not necessary.

An additional advantage is that these polymeric films are easily removable
before cross-linking as the polymer will readily form a viscous gel upon exposure
to humidified environments. The gel-like film can then be easily removed by
mechanical intervention. This is especially important in the field of
pharmaceuticals as the film can be separated from the active agent after the
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delivery device has been made. This separation allows for recovery of
expensive pharmaceutical active agents.

Examples

Example 1 2% (w/w) Hydroxyethylcellulose with a viscosity averaged molecular weight of
720,000 and 0.031 % (wlw based on total solids) riboflavin-5'-phosphate are
dissolved in distilled water. The resultant solution is allowed to deaerate in a
dark refrigerator overnight. The deaerated solution is poured onto a glass plate
and spread to a thickness of 12 mils (0.305 mm) and subsequently dried in a
conventional oven at 50°C to a moisture content of less than 10%. The film is
then exposed to a visible light source rated at 600 footcandles (Hotpack
environmental cabinet) for twenty-four hours. The resultant film is greater than
90% insoluble in water at ambient conditions.

Example 2 Three grams of hydroxyethylcellulose with a viscosity averaged molecular weight
of 90,000 and a degree of substitution of 2.5 (ie. Natrosol 250L) and 60 mg of
FD&C Blue #2 are dissolved in 100 ml of distilled water. The resultant solution
is poured onto glass plates and spread to a thickness of 12 mils (0.305 mm) and
subsequently dried in a conventional oven at 50°C to a moisture content of less
than 10%. The film is then exposed to a high intensity ultraviolet lightsource
(Mercury "H" bulb, 600 Watts/inch) for approximately 30 seconds. The resultant
film is crosslinked and is insoluble, but swellable in water.

Example 3182

The process of Example 2 is repeated with the exception that the catalyst used
is riboflavin-5'-phosphate.

Example 42% (w/w) Hydroxyethylcellulose with a viscosity averaged molecular weight of
720,000 and a degree of substitution of 2.5 (grade M) and 2% (w/w based on
total solids) riboflavin-5'-phosphate are dissolved in distilled water using a
homogenizer. The resultant solution is deaerated overnight in a dark
refrigerator. The deaerated solution is poured onto a glass plate which had
been preheated to 60°C and spread to a wet thickness of 0.040 inches
(approximately 1.0 mm). The film is subsequently dried in a conventional oven
at 60°C overnight. The film is then exposed to a high intensity ultraviolet
lightsource (Mercury "H" bulb, 600 Watts/inch) for 30 seconds. The resultant

)

film is approximately 75% insoluble in water at ambient conditions.

Example 5 The process of Example 4 is repeated with the exception that the energy source
used is visible light rated at 600 footcandles (Hotpack environmental cabinet)
and exposure is for twenty-four hours. The resultant film is in excess of 80%
insoluble in water at ambient conditions.

Example 6 1.5% (w/w) Hydroxyethylcellulose which has a viscosity averaged molecular
weight of 720,000 and a degree of substitution of 2.5 (Natrosol 250M) and
0.031 % (w/w) riboflavin-5'-phosphate are dissolved in distilled water using a
conventional mixer. The solution is deaerated overnight in a darkened
refrigerator.
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10.5 Kg of this solution is used to coat 1.25 Kg of 75 mg tablets containing
dextromethorphan using conventional spraying in a pharmaceutical coating pan.
The resultant coated tablets each contain 6.1 mg coating.

Example 7 The process of Example 6 is repeated except that the coated tablets are then
exposed to ultraviolet light (Mercury "H" bulb, 600 Watts/inch) on all sides for
approximately 60 seconds.

Example 8 A standard USP dissolution test in water USP is used to compare the coated
tablets of Examples 6 and 7. Exposure of the coated tablets to ultraviolet light
significantly decreased the dissolution rate. Eighty percent release occurred at
30 minutes for the tablets of Example 6, but did not occur until 150 minutes for
the tablets of Example 7, a five-fold difference.

Example 9The process of Example 7 is repeated except that the coating weight of each
tablet is 7.9 mg and the energy source is visible light rated at 600 footcandles
(Hotpack environmental cabinet) with exposure for 7 days.

Example 10The process of Example 9 is repeated except that each tablet is pierced with a
single hole measuring 0.025 inches (approximately 0.635 mm) in diameter to
form a release orifice.
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Example 11 A standard USP dissolution test in water USP is used to compare the coated
tablets of Examples 9 and 10. Eighty percent release occurred at 3 hours for the
tablets of Example 9, but did not occur until 4.1 hours for the tablets of Example
10.

Example 12 1.5% (w/w) Hydroxyethylcellulose which has a viscosity averaged molecular
weight of 720,000 and a degree of substitution of 2.5 (Natrosol 250M) and
0.031 % (w/w) riboflavin-5'-phosphate are dissolved in distilled water using a
conventional mixer. The solution is deaerated overnight in a darkened
refrigerator. 10.5 Kg of this solution is used to coat 1.25 Kg of 215 mg tablets
containing metoprolol fumarate using conventional spraying in a pharmaceutical

)

coating pan. The resultant coated tablets each contain 18 mg coating.

Example 13 The process of Example 12 is repeated except the coated tablets were exposed
to 600 foot-candles of visible light for 6 days.

Example 14 A standard USP dissolution test in water USP is used to compare the coated
tablets of Examples 12 and 13. Eighty percent release occurred at 3 hours for
the tablets of Example 13, but did not occur until 6 hours for the tablets of
Example 12.

The above description is for the purpose of teaching the person of ordinary skill
in the art how to practice the present invention and it is not intended to detail all
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those obvious modifications and variations of it wh ich will become apparent to
the skilled worker upon reading the description. It is intended, however, that all
such obvious modifications and variations be included within the scope of the
present invention and by the following claims.

What is claimed is:
1.

A method of preparing a hydrophilic cross-linked polymer which comprises
solubilizing a water-soluble polymer containing an effective amount of a
photosensitive or light degradable catalyst and exposing the solution to an
electromagnetic energy source.

)

2.

The method of claim 1, wherein the water-soluble polymer is selected from
the group consisting of the water-soluble polysaccharides, polyvinyl
alcohols, and poly(hydroxyethyl methacrylates).

3.

The method of claim 2, wherein the polymer is selected from the group
consisting of hydroxyethyl cellulose and hydroxypropyl methylcellulose.

4.

The method of claim 1, wherein the amount of polymer used is from about
1.0% to about 30% by weight of the solution.

5.

The method of claim 1, wherein the catalyst is selected from the group
consisting of flavins, Congo red, Evans blue, chlorazodin, erythrosine
(FD&C Red #3), FD&C Red #40, tartrazine (FD&C Yellow #5), fast green

)

FCF (FD&C Green #3), sunset yellow FCF (FD&C Yellow #6), brilliant blue
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FCF (FD&C Blue #1 ), and indigotine (FD&C Blue #2).

6.

The method of claim 5, wherein the flavinoid catalyst is selected from the
group consisting of riboflavin and riboflavin derivatives.

7.

The method of claim 5, wherein the flavinoid catalyst is riboflavin-5'phosphate or a salt thereof.

8.

The method of claim 1, wherein the amount of catalyst used is from about
0.1 to about 10% of the combined weight of the polymer and catalyst.

9.

)

The method of claim 1, wherein the energy source is light.

10. The method of claim 9, wherein the light is visible or ultraviolet.

11 . The method of claim 10, wherein the light is in the range of from
approximately 400 to approximately 700 nanometers.

12. The method of claim 1, which further comprises drying the solution before
exposing it to the energy source.

13. A hydrophilic crosslinked polymeric film prepared by the method of claim 1.

14. A pharmaceutical delivery system comprising the film of claim 13 and at
least one pharmaceutically acceptable active agent.

15. A method of coating a pharmaceutical dosage form with a hydrophilic
187

cross-linked polymer which comprises: admixing a water-soluble polymer
and an effective amount of a photosensitive or light degradable catalyst to
form a mixture; compression coating said mixture over a pharmaceutical
dosage form ; and exposing the coated dosage form to an electromagnetic
energy source.

Abstract

This invention pertains to cross-linked hydrophilic polymeric films, the process of
making such films, and their use. The films of this invention are produced by
solubilizing a water-soluble polymer with a photosensitive or light degradable
catalyst, optionally drying said solution, and exposing the solution to an energy
source, particularly light. These films are suitable for use as a carrier for
biologically active agents, such as pharmaceuticals, both human and veterinary,
insecticides, and fertilizers ; as hydrophilic membranes for separation processes;
as bandages for wound treatment; as body implants or as coatings for such
implants; and as coatings on glass, metal, wood or ceramics.
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